

CURRICULUM VITAE (CV)

First name	Hossein	
Surname	Nahrevanian	
Date of Birth	December 1959	
Place of Birth	Tehran, Iran	
Nationality	Iranian	

CONTACT PROFESSIONAL ADDRESSES

Department of Parasitology, Pasteur Institute of Iran, 69 Pasteur Avenue, Tehran 1316943551, Iran

Tel/Fax: (0098-21) 66968855 (Department)

Fax: (0098-21) 66465132 (Institute)

E-mail: mobcghn@yahoo.co.uk, hossein_nahrevanian@yahoo.co.uk, mobcghn@pasteur.ac.ir

Websites: <http://www.pasteur.ac.ir/parasitology/Nahrevanian.htm>

ACADEMIC POSITIONS

- **2012 – Now, Professor & CPL**, Department of Parasitology, Pasteur Institute of Iran
- **2008 – 2012, Associate professor & CPL**, Department of Parasitology, Pasteur Institute of Iran
- **2001 – 2007, Assistant professor & CPL**, Department of Parasitology, Pasteur Institute of Iran
- **1994 – 2000, Lecturer & Chief of Parasitology Laboratory (CPL)**, Department of Parasitology, Pasteur Institute of Iran
- **1989 – 1994, Chief technician of Parasitology**, Dept. of Parasitology, Pasteur Institute of Iran
- **1983 – 1989, Technician of Parasitology**, Department of Parasitology, Pasteur Institute of Iran

QUALIFICATION

- **PhD in Clinical Parasitology, (2001)** *Project title: The molecular biology of host responses to Plasmodium: Novel targets in the inflammatory and immune responses for the treatment of drug-sensitive and drug-resistant malaria*, School of Biological Sciences, Faculty of Medicine, The University of Manchester, UK.
- **MSPH in Medical Parasitology, (1993)** *Project title: Study of Cryptosporidiosis among the patients with acquired immunodeficiency in Tehran*. School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.
- **BSc in Biology (Animal Sciences), (1985)** Department of Biology, Faculty of Sciences, The University of Shahid Beheshti (Melli), Tehran, Iran.

RESEARCH EXPERIENCES AND SKILLS

- **In vitro:** Immunoparasitology, serology, Cell culture, Tissue preparation, Histopathology, Pharmacology, Immunofluorescence, Colorimetric and protein analysis assays, RNA & DNA extraction, RNA-transcription, PCR, RT-PCR, RFLP, Sequencing, ELISA, Flow cytometry, Western blotting etc.
- **Computing & Statistics:** Molecular biology (Proteomics, Genomics), Bioinformatics tools, Statistics software (SPSS, Graph Pad Prism), Photoshop, Animation Software, internet-searching, Web-design, Scientific Web Indexes (Magiran, SID, Iran Doc, Iran Medex, Scirus, ISI, Scopus, Index Copernicus, Bio Med Experts, Google Scholar ,.)
- **In vivo:** (UK home office license holder for animal working); handling, injection, surgery and measurement of physiological factors.

PUBLICATIONS

BOOKS

1. **Nahrevanian H**, Eskandarian A: *Malariology and Malaria Parasites (ملااریا شناسی و انگلهای مالاریا)*. 1st Edition, Khosravi Medical Publication, Tehran, Iran, 1384 (2005). (In Farsi)

JOURNALS (Full text in English)

1. Sadeghi S, Valadkhani Z, Sadeghi Tafreshi A, Arjmand M, **Nahrevanian H**, Vahabi F, Soori N, Mohammadi M, Meigooni M, Zamani Z. A study of synergy of combination of Eosin B with Chloroquine, Artemisinin, and Sulphadoxine-Pyrimethamine on *Plasmodium falciparum* in vitro and *Plasmodium berghei* in vivo. *Journal of Tropical Medicine*, ID 3013701, 2020; x(x):x-x. <https://doi.org/10.1155/2020/3013701>.
2. Papizadeh M, Rohani M, **Nahrevanian H**, Hosseini SN, Shojaosadati SA, Pourshafie MR. Using various approaches of design of experiments for high cell density production of the functionally probiotic *Lactobacillus plantarum* Strain RPR42 in a cane molasses-based medium. *Current Microbiology*, 2020; x(x):x-x. Apr 23, doi: 10.1007/s00284-020-01979-4. PMID: 32328749, ISI, IF:1.6
3. Papizadeh M, Rohani M, Hosseini SN, **Nahrevanian H**, Talebi M, Pourshafie MR. Screening for efficient nitrogen sources for overproduction of the biomass of the functionally probiotic *L. plantarum* strain RPR42 in a cane molasses-based medium. *AMB Express*, 2020; 10(53):1-14. doi 10.1186/s13568-020-00976-x. PMID: 32185601, PM, ISI, IF:0.x
4. Arbabi M, Soleimani Jevinani S, **Nahrevanian H**, Hooshyar H, Esmaeili Rastaghi AR, Delavari M, Ghasemi FS. The Effects of splenectomy on pattern of nitric oxide induction and pathogenesis of rodent malaria caused by *Plasmodium berghei* infection. *International Journal of Medical Laboratory*, 2019; 6(1):33-42. doi: PMID: PM, ISI, IF:0.x
5. Farahmand M, **Nahrevanian H**, Khalaj V, Mohebbi M, Barati M, Naderi S, Zarei Z, Khalili G. Assessment of recombinant A2-latex agglutination test (RA2-lat) and RA2-ELISA for detection of canine visceral leishmaniasis: A comparative field study with direct agglutination test in northwestern Iran. *Iranian Journal of Parasitology*, 2018; 13(2):172-179. doi: PMID: PM, ISI, IF:0.x
6. Papizadeh M, Rohani M, **Nahrevanian H**, Javadi AR, Pourshafie MR. Probiotic characters of *Bifidobacterium* and *Lactobacillus* are a result of the ongoing gene acquisition and genome minimization evolutionary trends. *Microbial Pathogenesis*, 2017; x(xx): x-x. PMID: 28826768 DOI: <https://doi.org/10.1016/j.micpath.2017.08.021>
7. Esfandiari B, **Nahrevanian H**, Pourshafie MR, Gouya MM, Khaki P, Mostafavi E, Darvish J, Hanifi H. Epidemiological distribution of rodents as potent reservoirs for infectious diseases in the provinces of Mazandaran, Gilan and Golestan, northern Iran. *Infectious Disease Reports*, 2017;9(2):6900. DOI: 10.4081/idr.2017.6900. PMID: 28626537. PM.
8. Miandoabi T, Hazrati Tappeh K, **Nahrevanian H**, Kazemi SM, Mohammadzadeh H, Hanifian H. Pharmacochimistry of Iranian Flora *Artemisia oliveriana* and its Antimalarial Effects on *Plasmodium berghei* in Vivo. *Advanced Studies in Biology*, 2017; 9(1): 43-51. ISI, IF:x
9. Papizadeh M, **Nahrevanian H**, Rohani M, Hosseini SN, Shojaosadati SA. *Lactobacillus rhamnosus* Gorbach-Goldin (GG): A Top Well-Researched Probiotic Strain. *Journal of Medical Bacteriology*, 2016; 5(5-6): 46-59. Index copernicus, DOAJ. <http://jmb.tums.ac.ir/index.php/jmb/article/view/278>
10. Haniloo A, Nemati S, **Nahrevanian H**, Fazaeli A, Farahmand M. In vivo and in vitro investigation on anti-leishmanial efficacy of artemisinin on Iranian strain of *Leishmania major*. *Advanced Studies in Medical Sciences*, 2016; 4(1): 1-11. <http://dx.doi.org/10.12988/asms.2016.662>
11. Naderi S, **Nahrevanian H**, Khalaj V, Farahmand M. Cloning, expression and purification of recombinant A2 protein from *Leishmania infantum* for diagnosis of visceral leishmaniasis in Iran. *Advanced Studies in Biology*, 2016; 8(3): 101-110. ISI, IF:x

12. Modaresinejad M, **Nahrevanian H**, Khatami S, Bagheri E. Biochemical association between essential trace elements and susceptibility to malaria in outbred mice after inhibition with dexamethasone or induction with lipopolysaccharide. *Advanced Studies in Biology*, 2016; 8(2): 91-99. **ISI, IF:x.**
13. Esfandiari B, **Nahrevanian H**, Pourshafie MR, Gouya MM, Khaki P, Mostafavi E, Darvish J, Moradi Bidhendi S, Hanifi H, Gharakhani M. Association of prevalent *Leptospira* species with different rodents of three Northern Provinces in Iran using microscopic agglutination test. *Advanced Studies in Biology*, 2016; 8(2); 53-63. **ISI, IF:x.**
14. Farahmand M, after **Nahrevanian H**. Application of recombinant proteins for sero-diagnosis of visceral leishmaniasis in human and dogs. *Iranian Biomedical Journal*, 2016; 20(3): 135-144. **ISI, PM, IF: 0.xx DOI: xxxxx**
15. Modaresinejad M, **Nahrevanian H**, Khatami S. Immunobiochemical study of host during malaria infection via nitric oxide pathway after modulation by lipopolysaccharide and dexamethasone in mice model. *International Journal of Biological Chemistry*, 2015; 9(5): 260-268. **ISI, IF: 0.371 DOI: 10.3923/ijbc.2015.;**
16. Faezi F, **Nahrevanian H**, Farahmand M, Sayyah M, Bidoki SK, Nemati S. Partial immunotherapy of leishmaniasis by *in vivo* trial of L-arginine in Balb/c mice infected with *Leishmania major* via nitric oxide pathway. *International Journal of Biological Chemistry*, 2015; 9(3): 110-122. **ISI, IF: 0.371 DOI: 10.3923/ijbc.2015;** <http://scialert.net/qredirect.php?doi=ijbc.2015.110.122&linkid=pdf>
17. **Nahrevanian H**, Assmar M, Zahraei SM, Mafi M, Masoumi Asl H, Ghasemi FS. Prevalence of sporozoan protozoa and enteroparasites in the gastroenteric patients referring to the healthcare centers of seven provinces of Iran. *International Journal of Enteric Pathogens*, 2015; 3(3): 19-24. e27087. **DOI: 10.17795/ijep27087**
18. Ghaffarinejad P, Farahmand M, **Nahrevanian H**, Mohebbali M, Zabolli F, Zarei Z, Akhoundi B, Barati M, Ghasemi FS. Diagnosis of *Leishmania infantum* using direct agglutination test and rKE16 dipstick rapid test in domestic dogs from Ardabil Province, Iran. *Research Journal of Parasitology*, 2015; 10(3):102-110. **ISI, IF:0.x, DOI: 10.3923/jp.2015.73.78 URL: <http://scialert.net/abstract/?doi=jp.2015.73.78>**
19. Rustaiyan A, Nahrevanian H, Zamani Z, Taherkhani M, Iravani A. An Investigation on Anti-malarial Effects of Tehranolide Isolated from *Artemisia diffusa* Against Human Malaria Parasite, *Plasmodium falciparum in vitro*. *Research Journal of Parasitology*, 2015; 10(2):73-78. **ISI, IF:0.x, DOI: 10.3923/jp.2015.73.78 URL: <http://scialert.net/abstract/?doi=jp.2015.73.78>**
20. Farahmand M, Khalaj V, Mohebbali M, Khalili G, Naderi S, **Nahrevanian H**, Ghaffarinejad P. Comparison of recombinant A2-ELISA with rKE16 dipstick and direct agglutination tests for diagnosis of visceral leishmaniasis in dogs in northwestern Iran. *Journal of the Brazilian Society of Tropical Medicine*, 2015; 48(2):188-93. **doi: 10.1590/0037-8682-0285-2014. PMID: 25992934. PM, ISI, IF:0.x**
21. Esfandiari B, Pourshafie MR, Gouya MM, Khaki P, Mostafavi E, Darvish J, Moradi Bidhendi S, Hanifi H, **Nahrevanian H**. An epidemiological comparative study on diagnosis of rodent leptospirosis in Mazandaran Province, northern Iran. *Epidemiology & Health*, 2015;;1-9. e2015012. **doi: 10.4178/epih/e2015012. PMID: 25773440. PM, ISI, IF:0.**
22. Najafzade M, Mosapour A, **Nahrevanian H**, Zamani Z, Javadian S, Mirkhani F. Effect of trinitroglycerin therapy on serum zinc and copper levels and liver enzyme activities in BALB/c mice infected with *Leishmania major* MRHO/IR/75/ER. *Iranian Journal of Basic Medical Sciences*, 2015; 18(3): 277-283. **PMID: 25945241. PM, ISI, IF:0.604**
23. Najafi M, **Nahrevanian H**, Khatami Sh, Masoudian N, Farahmand M. Investigation on bacterial lipopolysaccharide as immune system inducer on inbred Balb/c mice via nitric oxide pathway. *Advanced Studies in Biology*, 2015; 7(1): 1-10. **ISI**
24. Nikoukar LR, Nabavizadeh F, Mohamadi SM, Moslehi A, Hassanzadeh G, **Nahrevanian H**, Agah S. Protective effect of ghrelin in a rat model of celiac disease. *Acta Physiol Hung*. 2014;101(4):438-447. **PM, ISI, IF:0.747**

25. Esmaeili Rastaghi AR, Nedaei F, **Nahrevanian H**, Hoseinkhan N. Genetic diversity and effect of natural selection at apical membrane antigen-1 (AMA-1) among Iranian *Plasmodium vivax* isolates. *Folia Parasitologica*, 2014; 61(5): 385-393. **ISI, PM, IF: 1.211**
26. Moslehi A, Nabavizadeh F, Dehpou AR, Tavanga SM, Hassanzadeh G, Zekri A, **Nahrevanian H**, Sohanaki H. Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice. *Acta Physiol Hung*. 2014;101(3):341-352. **Erratum: Acta Physiol Hung. 2014;101(4):524. **PM, ISI, IF:0.747****
27. Taherkhani M, Rustaiyan A, **Nahrevanian H**, Salehizadeh E. In vivo antimalarial activity of Iranian flora *Artemisia oliveriana* J. Gay ex DC. extract and its comparison with other anti-malarial drugs against *Plasmodium berghei* in mice model. *Journal of Biologically Active Products from Nature*, 2013; 3(3): 173-182.
28. Taherkhani M, Rustaiyan A, **Nahrevanian H**, Naeimi S, Taherkhani T. Comparison of antimalarial activity of *Artemisia turanica* extract with current drugs *in vivo*. *Journal of Vector Born Diseases*, 2013; 50(1): 51-56. **PM, ISI, IF:1.177**
29. Shahi M, Mohajery M, Shamsian SAA, **Nahrevanian H**, Yazdanpanah SMJ. Comparison of Th1 and Th2 responses in non-healing and healing patients with cutaneous leishmaniasis. *Reports of Biochemistry & Molecular Biology*, 2013; 1(2): 1-6. **PM, Chemical Abstracts Service (CAS), Index Copernicus**
30. Sadeghi Niaraki M, Nabavizadeh F, Vaezi GhH, Alizadeh AM, **Nahrevanian H**, Moslehi A, Azizian A. Protective effect of Ghrelin on sodium valproate- induced liver injury in rat. *Journal of Stress Physiology & Biochemistry*, 2013; 9(1): 96-105. **Index Copernicus**
31. Sar Kheyr Kheyabany S, Nabavizadeh F, Vaezi GhH, Alizadeh AM, **Nahrevanian H**, Moslehi A, Azizian A. Protective effect of Ghrelin on Isoniazid-induced liver injury in rat. *Journal of Stress Physiology & Biochemistry*, 2013; 9(1): 273-282. **Index Copernicus**
32. Ahmadi A, Sayyah M, Khoshkholgh-Sima B, Choopani S, Kazemi J, Sadegh M, Moradpour F, **Nahrevanian H**. Intra-hippocampal injection of lipopolysaccharide inhibits kindled seizures and retards kindling rate in adult rats. *Experimental Brain Research*. 2013; 226(1): 107-120. **PM, ISI, IF:2.395**
33. Nemati S, **Nahrevanian H**, Haniloo A, Farahmand M. Investigation on nitric oxide and c-reactive protein involvement in anti-leishmanial effects of Artemisinin and Glucantim on cutaneous leishmaniasis. *Advanced Studies in Biology*, 2013; 5(1): 27-36. **ISI**. <http://dx.doi.org/10.12988/asb.2013.13003>
34. **Nahrvevanian H**, Jafary SP, Nemati S, Farahmand M, Omidinia E. Evaluation of anti-leishmanial effects of Killed *Leishmania* Vaccine with BCG adjuvant in BALB/c mice infected with *Leishmania major* MRHO/IR/75/ER. *Folia Parasitologica*, 2013; 60(1): 1-6. **ISI, PM, IF:1.812**
35. Nemati S, Jafary SP, **Nahrevanian H**, Farahmand M, Nahrevanian S. Immuno-biochemical alterations in *Leishmania major* infected Balb/c mice after immunization with Killed *Leishmania* Vaccine and BCG as adjuvant. *Current Research Journal of Biological Sciences*, 2012; 4(6): 706-712. **ISI, IF:**
36. Zamani Z, Sadeghi Tafreshi A, **Nahrevanian H**, Lame-Rad B, Pourfallah F, Eslamifar H, Sadeghi S, Vahabi F, Iravani I, Arjmand M. Efficacy of Eosin B as a new anti malarial drug in a murine model. *Malaria Research and Treatment*, 2012; ID 381724: 1-5. **PM, IF:**
37. Sanati H, Nourollahi Fard SR, **Nahrevanian H**, Khalili M, Safari Z. Seroprevalence of *Toxoplasma gondii* antibodies in dairy cows in Kerman Province, South East Iran. *Current Research Journal of Biological Sciences*, 2012; 4(4): 417-421. **ISI, IF:**
38. **Nahrevanian H**, Jalalian M, Farahmand M, Assmar M, Esmaeili Rastaghi AR, Sayyah M. Inhibition of murine systemic leishmaniasis by acetyl salicylic acid via nitric oxide immunomodulation. *Iranian Journal of Parasitology*, 2012; 7(2): 21-28. **ISI, PM, IF: 0.605**
39. Bahrami AM, Doosti AZ, **Nahrevanian H**, Shamsi M. Pathological study on parasitism in racing pigeons; An indication of its effects on community health. *Advances in Environmental Biology*, 2012; 6(2): 726-732. **ISI, IF:**

40. **Nahrevanian H**, Sheykhkanlooye Milan B, Kazemi M, Hajhosseini R, Soleymani Mashhadi S, Nahrevanian S. Antimalarial effects of Iranian flora *Artemisia sieberi* on *Plasmodium berghei* in vivo to mice and phytochemistry of its herbal extracts. *Malaria Research and Treatment*, 2012; ID 727032: 1-8. [PM](#), [IF:](#)
41. Salehizadeh E, **Nahrvevanian H**, Farahmand M, Hajihosseini R, Saghiri R, Khalili G: In vivo application of killed *Leishmania* vaccine and Imiquimod as adjuvant in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER as Iranian strain. *Research Journal of Parasitology*, 2011; 6(4): 116-126. [ISI](#), [IF:](#)
42. Fallahi S, Nabavizadeh F, Sadr SS, Alizadeh AM, Adeli S, **Nahrevanian H**, Sadeghipour HR, Hasanazadeh Gh: The effects of Leptin on gastric ulcer due to physical and psychological stress: Involvement of nitric oxide and prostaglandin E2. *Journal of Stress Physiology & Biochemistry*, 2011; 7(4): 301-310. [Index Copernicus](#)
43. Bahrami AM, Doosti AZ, **Nahrevanian H**, Noorian AM, Ahmadi Asbchin S. Epidemiological survey of gastro-intestinal parasites in stray dogs and cats. *Australian Journal of Basic and Applied Sciences*, 2011; 5(9): 1944-1948. [ISI](#), [IF:](#)
44. Moloudi R, Nabavizadeh F, **Nahrevanian H**, Hassanzadeh Gh. Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid- pepsin perfusion in male rats. *Peptides*, 2011; 32(10): 2086-2090. [ISI](#), [PM](#), [IF: 2.654](#)
45. Rustaiyan A, **Nahrevanian H**, Kazemi M. Isolation of Artediffusin (Tehranolide) as a new antimalarial agent. *Asian Journal of Chemistry*, 2011; 23(11):4810-4814. [ISI](#), [IF: 0.247](#)
46. Farahmand M, Atashi Shirazi H, **Nahrevanian H**, Hajjaran H. Molecular analysis of A2-genes encoding stage-specific S antigen-like proteins among isolates from Iranian cutaneous and visceral leishmaniasis. *Iranian Journal of Basic Medical Sciences*, 2011; 14(5):407-413. [ISI](#), [PM](#), [IF:](#)
47. **Nahrevanian H**, Aboufazeli F, Kazemi SM, Hajihosseini R, Naeimi S: Phytochemical evaluation and antimalarial effects of *Artemisia turanica* herbal extracts as an Iranian flora on *Plasmodium berghei* in vivo. *Journal of Natural Remedies*, 2011; 11(2):167-176.
48. Vahedian M, Nabavizadeh F, Vahedian J, Keshavarz M, **Nahrevanian H**, Mirershadi F. Lead exposure changes gastric motility in rats: Role of nitric oxide (NO). *Achieve of Iranian Medicine*. 2011;14(4):266-269. [ISI](#), [PM](#), [IF: 1.348](#)
49. Farahmand M, **Nahrevanian H**, Atashi Shirazi H, Naeimi S, Farzanehnejad Z: An overview of diagnostic and epidemiologic reappraisal of cutaneous leishmaniasis in Iran. *Brazilian Journal of Infectious Diseases*, 2011; 15(1):17-21. [ISI](#), [PM](#), [IF: 0.811](#)
50. Tabatabaee P, Abolhassani M, Mahdavi M, **Nahrevanian H**, Azadmanesh K: *Leishmania major*: Secreted antigens of *Leishmania major* promastigotes shift the immune response of the C57BL/6 mice toward Th2 in vitro. *Experimental Parasitology*, 2011; 127(1): 46-51. [ISI](#), [PM](#), [IF: 1.869](#)
51. Hosseini M, Sadat Dastghaib S, Rafatpanah H, Hadjzadeh M, **Nahrevanian H**, Farrokhi I: Nitric oxide contributes to learning and memory deficits observed in hypothyroid rats during neonatal and juvenile growth. *Clinics*, 2010; 65(11): 1175-1181. [ISI](#), [PM](#), [IF: 1.422](#)
52. Nabavizadeh F, Moloudi R, Dehpour AR, **Nahrevanian H**, Shahvaisi K, Salimi E: The Effects of cholestasis and cirrhosis on gastric acid and pepsin secretions in rat: Involvement of nitric oxide. *Iranian Journal of Basic Medical Sciences*, 2010; 13(4): 207-212. [ISI](#), [IF:](#)
53. Golestan Jahromi M, Nabavizadeh F, Vahedian J, **Nahrevanian H**, Dehpour AR, Zare-Mehrjardi A: Protective effect of ghrelin on acetaminophen induced liver injury in rat. *Peptides*, 2010; 31(X): 2114---2117. [ISI](#), [PM](#), [IF: 2.654](#)
54. **Nahrevanian H**, Azarinoosh SA, Esfandiari B, Ziapoor SP, Shadifar M, Amirbozorgy G, Hayati E, Davoodi J. Current situation of *Cryptosporidium* and other enteroparasites among patients with gastroenteritis from western cities of Mazandaran Province, Iran, during 2007-08. *Journal of Gastroenterology and Hepatology from Bed to Bench*, 2010; 3(3):120-125.

55. Roghani M, Mahboudi F, Saharian MA, Etemadifar M, Esfahani AN, **Nahrevanian H**, Elahi E: Concentrations of nitric oxide metabolites in the serum of Iranian multiple sclerosis patients. *Journal of the Neurological Sciences*. 2010; 294(1-2): 92-94. [ISI](#), [PM](#), [IF: 2.167](#)
56. **Nahrevanian H**, Esmaeili B, Kazemi M, Nazem H, Amini M: In vivo antimalarial effects of Iranian flora *Artemisia khorassanica* against *Plasmodium berghei* and pharmacochemistry of its natural components. *Iranian Journal of Parasitology*, 2010; 5(1): 6-19. [ISI](#), [PM](#), [IF: 0.605](#)
57. **Nahrevanian H**: Involvement of nitric oxide and its up/down stream molecules in the immunity of parasitic infections. *Brazilian Journal of Infectious Diseases*, 2009; 13(6): 440-448. [ISI](#), [PM](#), [IF: 0.811](#)
58. Davachi S, **Nahrevanian H**, Omidinia E, Hajihosseini R, Amini M, Farahmand M, Mirkhani F, Javadian S: Biochemical alterations of liver enzymes and microelements during *Leishmania major* infection in BALB/c mice after treatment with Paromomycin. *Pharmacologyonline*, 2009; 3: 424-436.
59. **Nahrevanian H**, Hajihosseini R, Arjmand M, Farahmand M, Ghasemi F: Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with *Leishmania major*. *Southeast Asian Journal of Tropical Medicine and Public Health*, 2009; 40(6):1188-1198. [ISI](#), [PM](#), [IF:](#)
60. Amini M, **Nahrevanian H**, Khatami S, Farahmand M, Mirkhani F, Javadian S: Biochemical association between the essential trace elements and susceptibility to *Leishmania major* in BALB/c and C57BL/6 mice. *Brazilian Journal of Infectious Diseases*, 2009; 13(2):83-85. [ISI](#), [PM](#), [IF: 0.811](#)
61. Sharif M, Daryani A, Rostami M, **Nahrevanian H**, Azadbakht M: Evaluation of antileishmanial efficacy by in vivo administration of herbal extract *Artemisia auchery* on *Leishmania major* in BALB/C mice. *Pharmacologyonline*, 2009; 2: 477-485.
62. **Nahrevanian H**, Najafzadeh M, Hajihosseini R, Nazem H, Farahmand M, Zamani Z: The therapeutic antileishmanial effects of Trinitroglycerin in BALB/C mice infected with *Leishmania major* via nitric oxide pathway. *Korean Journal of Parasitology*, 2009; 47(2): 109-115. [ISI](#), [PM](#), [IF: 0.963](#)
63. **Nahrevanian H**, Amini M: Nitric oxide functions; an emphasis on its diversity in infectious diseases. *Iranian Journal of Basic Medical Sciences*, 2009; 11(4): 197-204. [ISI](#), [IF:](#)
64. Esfandiari B, Fayaz A, **Nahrevanian H**, Hashemi SA, Simani S, Behzadi R, Amini M, Kavoosian S, Maghsoudi F: Comparison of animal rabies from Northern Provinces of Iran referred to the Amol Research Center (ARC) during 2007. *Internet Journal of Microbiology*. 2009; 6(1): 1-7.
65. Amini M, **Nahrevanian H**, Farahmand M, Khatami S, Mirkhani F, Javadian S: Immuno-biochemical variation in susceptible BALB/c and resistant C57BL/6 mice infected with Iranian strain of cutaneous leishmaniasis; *Leishmania major* MRHO/IR/75/ER. *Internet Journal of Infectious Diseases*, 2009; 7(1): 1-4.
66. Rustaiyan A, **Nahrevanian H**, Kazemi M: A New Antimalarial Agent; Effect of Extracts of *Artemisia diffusa* against *Plasmodium berghei*. *Pharmacognosy Magazine*, 2009; 4(17): 1-7. [ISI](#), [IF:](#)
67. Amini M, **Nahrevanian H**, Farahmand M: Pathogenicity variations of susceptibility and resistance to *Leishmania major* MRHO/IR/75/ER strain in BALB/c and C57BL/6 mice. *Iranian Journal of Parasitology*, 2008; 3(4): 51-59. [ISI](#), [PM](#), [IF: 0.605](#)
68. Farahmand M, Assmar M, **Nahrevanian H**, Farzanehnejad Z, PlazaK N: Cutaneous leishmaniasis in patients referred to the Pasteur Institute of Iran during 2003-2006. *Internet Journal of Parasitic Diseases*, 2008; 3(2): 1-7.
69. Esfandiari B, Youssefi MR, **Nahrevanian H**, Keighobadi M, Aghvami Amoli Sh, Ziapour P: Incidence of Pediculosis in patients referring to Shemiranat Health Center, Tehran during 2002 to 2006. *Internet Journal of Parasitic Diseases*, 2008; 3(1): 1-6.

70. **Nahrevanian H**, Gholizadeh J, Farahmand M, Assmar M: Patterns of co-association of C-reactive protein and nitric oxide in malaria in endemic areas of Iran. *Memórias Do Instituto Oswaldo Cruz*, 2008; 103(1): 39-44. [ISI](#), [PM](#), [IF: 2.058](#)
71. **Nahrevanian H**, Assmar M: Cryptosporidiosis in immunocompromised patients in the Islamic Republic of Iran. *Journal of Microbiology Immunology & Infection*, 2008; 41(1): 74-77. [ISI](#), [PM](#), [IF: 1.116](#)
72. Farahmand M, **Nahrevanian H**, Assmar M, Mohebbali M, Zarei Z: Expression of A2 proteins in amastigotes of *Leishmania infantum* produced from canine isolates collected in the district of Meshkinshahr, in north-western Iran. *Annals of Tropical Medicine and Parasitology*, 2008; 102(1): 81-84. [ISI](#), [PM](#), [IF: 1.288](#)
73. Esfandiari B, Youssefi MR, Keighobadi M, **Nahrevanian H**: *In vivo* evaluation of anti-parasitic effects of *Artemisia absinthium* extracts on *Syphacia* parasite. *Internet Journal of Parasitic Diseases*, 2007; 2(2): 1-5.
74. Hashemi SA, Esfandiari B, Fayaz A, **Nahrevanian H**, Behzadi R, Kavosian S, Ziapour SP, Ghobadi-rad S, Maghsoudi F: Investigation on animal and human rabies in cases from Mazandaran and Golestan provinces referred to the Amol Research Center, Northern Iran in 2003–2005. *Internet Journal of Microbiology*. 2007; 4(1): 1-4.
75. **Nahrevanian H**, Farahmand M, Aghighi Z, Assmar M, Amirkhani A: Pharmacological evaluation of anti-leishmanial activity by *in vivo* nitric oxide modulation in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER; An Iranian strain of cutaneous leishmaniasis. *Experimental Parasitology*, 2007; 116(3): 233-240. [ISI](#), [PM](#), [IF: 1.869](#)
76. **Nahrevanian H**, Assmar M, Ghorbani Samin M: Cryptosporidiosis among immunocompetent patients with gastroenteritis in Tehran, I. R. Iran; A comparison with other enteropathogenic parasites. *Journal of Microbiology Immunology & Infection*, 2007; 40(2): 154-156. [ISI](#), [PM](#), [IF: 1.116](#)
77. **Nahrevanian H**: Immune effector mechanisms of nitric oxide pathway in malaria: Cytotoxicity versus cytoprotection. *Brazilian Journal of Infectious Diseases*, 2006; 10(4): 283-292. [ISI](#), [PM](#), [IF: 0.811](#)
78. **Nahrevanian H**, Assmar M: A case report of Cryptosporidiosis and Isosporiasis in AIDS patients in Iran, *The Journal of Tropical Medicine & Parasitology*, 2006; 29(1): 33-36.
79. **Nahrevanian H**, Gholizadeh J, Farahmand M, Assmar M, Sharifi K, Ayatollahi Mousavi SA, Abolhassani M: Nitric oxide induction as a novel immunoepidemiological target in malaria-infected patients from endemic areas of the Islamic Republic of Iran. *Scandinavian Journal of Clinical & Laboratory Investigation*, 2006; 66(3): 201-210. [ISI](#), [PM](#), [IF: 1.629](#)
80. **Nahrevanian H**, Dascombe MJ: Simultaneous increases in immune competent cells and nitric oxide in the spleen during *Plasmodium berghei* infection in mice. *Journal of Microbiology Immunology & Infection*, 2006; 39(1): 11-17. [ISI](#), [PM](#), [IF: 1.116](#)
81. **Nahrevanian H**, Gholizadeh SJ, Farahmand M, Aghighi Z, Assmar M, Abolhassani M: Reactive nitrogen intermediate production and tolerance variability in different mouse strains after *in vivo* treatment with lipopolysaccharide from *Salmonella abortus equi*. *Journal of Microbiology Immunology & Infection*, 2005; 38(3): 164-168. [ISI](#), [PM](#), [IF: 1.116](#)
82. **Nahrevanian H**: Nitric oxide and reactive nitrogen intermediates are released by immune response during malaria infection. *Journal of the Communicable Diseases*, 2004; 3(3): 23-26. [ISI](#), [IF:](#)
83. Assmar M, Terhovanessian A, **Nahrevanian H**, Yassaei F, Esmaeili AR: Molecular detection of congenital toxoplasmosis by nested- PCR in Iran. *Journal of the Communicable Diseases*, 2004; 3(3): 27-29. [ISI](#), [IF:](#)
84. **Nahrevanian H**: The penetration of *Plasmodium* into red blood cell is a protective mechanism of malaria parasite against high levels of accumulated nitric oxide in blood circulation. *Journal of Parasitic Diseases*, 2004; 28(2): 83-89.
85. Assmar M, Yassaei F, Terhovanessian A, Esmaeili AR, **Nahrevanian H**, Hassan N, Farzaneh Nezhad Z, Naddaf SR: Prenatal diagnosis of congenital Toxoplasmosis: validity of PCR using

amniotic fluid against indirect fluorescent antibody assay in mothers. *Iranian Journal Public Health*, 2004; 33(1): 1-4. [ISI](#), [IF: 0.321](#)

86. **Nahrevanian H**: Nitric oxide involvement during malaria infection; Immunological concepts, mechanisms and complexities; A novel review. *The Journal of Tropical Medicine & Parasitology*, 2004; 27(2): 93-101.
87. **Nahrevanian H**: Direct monitoring of *in situ* and *in vitro* nitric oxide release in the brain during malaria infection with *Plasmodium berghei* N/13/1A, *The Journal of Tropical Medicine & Parasitology*, 2004; 27(1): 1-6.
88. Assmar M, Terhovanessian A, Jahani MR, **Nahrevanian H**, Amirkhani A, Piazak N, Esmaeili AR, Farahmand M, Zare M: Molecular Epidemiology of Malaria Disease in Endemic Areas of Iran. *Southeast Asian Journal Tropical Medicine & Public Health*, 2003; 34(S2): 15-19. [ISI](#), [PM](#), [IF](#):
89. **Nahrevanian H**, Dascombe MJ: The role of nitric oxide and its up/downstream molecules in malaria: cytotoxic or preventive? *Southeast Asian Journal Tropical Medicine & Public Health*, 2003; 34(S2): 44-50. [ISI](#), [PM](#), [IF](#):
90. **Nahrevanian H**, Dascombe MJ: Reactive nitrogen intermediate (RNI) levels inside and outside *Plasmodium* infected red blood cells in murine malaria, *The Journal of Tropical Medicine & Parasitology*, 2003; 26(1): 13-19.
91. Dascombe MJ, **Nahrevanian H**: Pharmacological assessment of the role of nitric oxide in mice infected with lethal and nonlethal species of malaria, *Parasite Immunology*, 2003; 25(3): 149-159. [ISI](#), [PM](#), [IF: 2.357](#)
92. **Nahrevanian H**, Dascombe MJ: Expression of inducible nitric oxide synthase (iNOS) mRNA in target organs of lethal and non-lethal strains of murine malaria, *Parasite Immunology*, 2002; 24(9-10): 471-478. [ISI](#), [PM](#), [IF: 2.357](#)
93. **Nahrevanian H**, Dascombe MJ: Nitric oxide and reactive nitrogen intermediates during lethal and non-lethal strains of murine malaria, *Parasite Immunology*, 2001; 23: 491-501. [ISI](#), [PM](#), [IF: 2.357](#)
94. Assmar M, Milaninia A, Amirkhani A, Yadegari D, Forghanparast K, **Nahrevanian H**, Piazak N, Esmaeili AR, Hovanesian A, Valadkhani Z: Sero-epidemiological investigation of Fascioliasis in northern Iran, *Medical Journal of Islamic Republic of Iran*, 1991; 5(1,2): 23-27. [ISI](#), [PM](#), [IF](#):

JOURNALS (Full text in Farsi)

1. Ghasemi F, **Nahrevanian H**. Application of L-Arginine as nitric oxide inducer and Indomethacin as prostaglandin inhibitor in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER. *Journal of Army University of Medical Sciences*. 2013; 11 (1) : 1-10.
2. Rostami M, **Nahrevanian H**, Farahmand M, Sharif M. The effects of methanolic extract of *Artemisia auchery* Bloss. on cutaneous lesions caused by *Leishmania major* in BALB/C mice. *Journal of Herbal Drugs*, 2012; 2(4): 269-274.
3. Taghipour Bazargani T, Moaddab SH, Raoufi A, Barin A, Abdollahipour GR, **Nahrevanian H**, Masoudifard M, Taheri M, Bamonar AR. Survey of ERU Frequency and its associated factors among different horse breeds in riding clubs in Tehran suburb. *Journal of veterinary Medicine (SANANDAJ)* 2011; 5(2):1-9. [ISC](#), [IF: 0.029](#)
4. **Nahrevanian H**, Azarinoosh SA, Esfandiari B, Amirkhani A, Ziapoor SP, Shadifar M: The frequency of Cryptosporidiosis among gastroenteritic patients in western cities of Mazandaran Province (2007-09). *Journal of Qazvin University of Medical Sciences*, 2011; 15(1): 78-86.
5. Jalalian M, **Nahrevanian H**, Assmar M, Esmaeili Rastaghi AR, Farahmand M, Amini M: Immunoparasitology of antileishmanial effects of ASA in Balb/c mice infected with *Leishmania major* via NO and CRP pathways. *Journal of Biological Sciences of Lahijan IAU*, 2010; 4(2): 35-46.
6. Azarinoosh SA, **Nahrevanian H**, Assmar M, Esfandiari B, Amirkhani A: Simultaneous prevalence of *Blastocystis hominis* in patients with Giardiasis from Tonekabon city, Mazandaran province, Iran. *Journal of Biological Sciences of Lahijan IAU*, 2010; 3(4): 1-7.

7. **Nahrevanian H**, Abedinzadeh L, Ghasemi K, Eslamifar A, Ajdari S, Esfandiari B, Rahbari S, Ezzati Mirhashemi M: Proliferation of *Cryptosporidium* sp. in immunosuppressed Balb/c and C57bl/6 mice for modeling of Cryptosporidiosis in immunodeficiency. *Pajoohandeh Journal of Shahid Beheshti University of Medical Sciences*, 2010; 15(1): 31-37.
8. **Nahrevanian H**, Assmar M, Raeisi A, Farahmand M, Farzaneh Nejad Z, Arshi Sh, Sadeghi H, Garousi B, Emdadi D, Seifnejad Sh, Kazemi asl SM: Seroparasitological evaluation of *Plasmodium vivax* malaria and stability of antiplasmodial antibodies in Parsabad city, Ardabil Province. *Journal of Shahrekord University of Medical Sciences*, 2010; 11(4): 57-63.
9. Vahabzadeh H, **Nahrevanian H**, Assmar M, Zahraei SM, Habibzadeh M, Mafi M: Prevalence rate of enteropathogenic parasites and sporozoan protozoa in gastroenteritic patients from Gilan province, Iran. *Journal of Biological Sciences of Lahijan IAU*, 2009; 3(2): 81-91.
10. Mohajeri M, Shamsian AA, **Nahrevanian H**, Mahmoudi M, Yazdanpanah SMJ, Fathi Moghaddam F, Shahi M: Comparison of IL-5, IL-10, IL-12 and IL-18 levels secreted from PMBC cells of patients with healing and non-healing forms of cutaneous leishmaniasis. *Scientific Journal of Hamadan University of Medical Sciences & Health Services*, 2009; 16(3): 5-11.
11. Fallahi Sh, Badparva E, **Nahrevanian H**, Mohammadi M, Chegeni Sharafi A, Ebrahimzadeh F: Comparison of the prevalence of Intestinal Parasites in HIV+ and AIDS Patients in Khorramabad city in 2006-2007. *Journal of Kerman University of Medical Sciences*, 2009; 16(2): 166-172.
12. Mohajeri M, Shamsian AA, **Nahrevanian H**, Mahmoudi M, Yazdanpanah MJ, Shahi M: Evaluation of Th1 & Th2 cytokines secreted in the healing and non-healing cases of cutaneous leishmaniasis treated by Glucantime. *Journal of Mashhad University of Medical Sciences*, 2008; 51(3): 149-154.
13. Ghorbannia Delavar A, **Nahrevanian H**, Assmar M, Amirkhani A, Esfandiary B: Frequency of Cryptosporidiosis, Isosporiasis and other enteropathogenic parasites in gastroenteritic patients (Babol and Babolsar; 2005-2006). *Journal of Babol University of Medical Sciences*, 2008; 10(2): 56-67.
14. Fallahi Sh, Badparva E, **Nahrevanian H**, Chegeni Sharafi A, Ebrahimzadeh F: Prevalence of Intestinal Parasites in HIV+ and AIDS Patients Khorramabad 2006. *Yafteh (Journal of Lorestan University of Medical Sciences)*, 2007; 9(2): 39-47.
15. **Nahrevanian H**, Assmar M, Ghorbani Samin M: A study on Cryptosporidiosis among patients with acquired immunodeficiency in the Great Tehran. *Scientific Journal of School of Public Health & Institute of Public Health Research*, 2004; 3(2): 77-86.
16. Assmar M, Esmaeili AR, Amirkhani A, **Nahrevanian H**: The prevalence rate of intestinal parasites in the primary school pupils of Mazandaran province. *Journal of Tropical Infectious Diseases*. 1998; 3(9): 53-59.
17. **Nahrevanian H**: Cryptosporidiosis and treatment, *Journal of Pharmaceutical Razi*, 1994; 11(5): 37-39.
18. Assmar M, Forghanparast K, Yadegari D, Azmoodeh M, Nimasa A, **Nahrevanian H**, Esmaeili AR, Golparvar G: The study of Fascioliasis in province of Gilan (Bandar Anzali), *J.of Pasteur Institute of Iran*, 1990; 1(5,6): 57-66.

ABSTRACTS in JOURNALS

1. Rahmati H, Esmaeili Rastaghi AR, Modiri L, **Nahrevanian H**, Assmar M. Coparison of animals and human sera in the accessory factor in the Sabin-Feldman Dye Test for detection of toxoplasmosis Genetic characteristics of the apical membrane antigen-1 (AMA-1) in *Plasmodium vivax* isolates from Iran. *Tropical Medicine & International Health*. 2012; 9(S 1): 157.
2. Esmaeili Rastaghi AR, Hoseinkhan N, **Nahrevanian H**: Genetic characteristics of the apical membrane antigen-1 (AMA-1) in *Plasmodium vivax* isolates from Iran. *Tropical Medicine & International Health*. 2011; 16(SI) Supp.1: 112.

3. Farahmand M, Shirazi HA, **Nahrevanian H**, Naeimi S: Evaluation of cutaneous leishmaniasis in patients referred to Pasteur Institute of Iran. *Tropical Medicine & International Health*. 2011; 16(SI) Supp.1: 181.
4. **Nahrevanian H**, Nemati S, Haniloo A, Farahmand M, Fazaeli A: Anti-leishmanial effects of artemisinin in comparison with glucantim on *Leishmania major* in vitro. *Tropical Medicine & International Health*. 2011; 16(SI) Supp.1: 230.
5. **Nahrevanian H**, Salehizadeh E, Farahmand M, Hajihosseini R, Alimohammadian MH, Saghir R, Javadian S: Application of killed *Leishmania* vaccine's efficacy with imiquimod as adjuvant in inhibition of visceralization of *L. major* in BALB/c mice. *Tropical Medicine & International Health*. 2011; 16(SI) Supp.1: 230.
6. **Nahrevanian H**, Farahmand M, Nahrevanian S, Ajdari S, Amini M, Ezzati Mirhashemi M: Isolation of cryptosporidiosis from different sources and its proliferation in experimentally immunosuppressed mice; representing of different variations. *Gut*, 2011; 60 (Suppl 3) A387, P1360.
7. **Nahrevanian H**, Abedinzadeh L, Eslamifar A, Amini M, Naeimi S: Different patterns of cryptosporidiosis in two immune suppressed inbred mice models. *Gut*, 2011; 60 (Suppl 3) A387, P1361.
8. Hosseini M, Dastghaib SS, **Nahrevanian H**, Farrokhi I: Methimazole – induced hypothyroidism during lactation affects brain nitric oxide levels in offspring rats. *Clinical Biochemistry*, 2011; 44(13),S1: S58.
9. Nemati S, **Nahrevanian H**, Haniloo A, Farahmand M, Fazaeli A: Investigation on anti-leishmanial effects of artemisinin in comparison with glucantim on *Leishmania major* in vitro. *International Journal of Infectious Diseases*, 2011; 15(S1): PP-187, S97.
10. **Nahrevanian H**, Farahmand M, Ajdari S, Amini M, E Mirhashemi M: Protein variations of *Cryptosporidium* spp. from different sources after proliferation in experimentally immunosuppressed mice. *International Journal of Infectious Diseases*, 2011; 15(S1): PP-173, S93.
11. Jafary SP, **Nahrevanian H**, Omidinia E, Farahmand M, Khalili G, Hosseini Z, Naeimi S: Immunobiochemical evaluation of killed leishmania vaccine (KLV) with BCG adjuvant for inhibition of visceralization of *Leishmania major* in Balb/c mice. *International Journal of Infectious Diseases*, 2011; 15(S1): PP-051, S59.
12. **Nahrevanian H**, Abedinzadeh L, Eslamifar A, Amini M, Naeimi S: Pathophysiology of cryptosporidiosis in immunosuppressed Balb/c and C57bl/6 mice Models. *International Journal of Infectious Diseases*, 2011; 15(S1): PP-045, S58.
13. Salehizadeh E, **Nahrevanian H**, Farahmand M, Hajihosseini SR, Alimohammadian MH, Saghir R, Naeimi S: In vivo investigation of Killed *Leishmania* Vaccine's (KLV) efficacy with Imiquimod (IMQ) as adjuvant in inhibition of visceralization of *Leishmania major* in Balb/c model. *International Journal of Infectious Diseases*, 2011; 15(S1): OL-031, S25.
14. Zamani Z, Sadeghi Tafreshi A, **Nahrevanian H**, Arjmand M, Lame-Rad B, Sadeghi S, Mirkhani F, Eslamifar A, Pourfallah F, Iravani A, Wahabi F: A new anti-malarial drug against murine malaria. *BMC Proceedings*, 2011; 5(S 1): P17.
15. Noorolahi SR, **Nahrevanian H**, Sanati H: Detection of antibodies against *Toxoplasma gondii* in sub-urban cattle of Kerman using modified agglutination test (MAT). *Iranian Journal for Parasitology*, 2010; 5(S1): p33.
16. Vahabzadeh H, **Nahrevanian H**, Assmar M, Habibzadeh M, Daneshi M, Zahraei SM, Mafi M: An investigation on *Cyclospora* infection isolated from gastroenteritic patients of Gilan and Ghazvin provinces in Iran. *Iranian Journal for Parasitology*, 2010; 5(S1): p38.
17. **Nahrevanian H**, Assmar M, Zahraei M, Mafi M, Masoumi Asl H, Motevallian A, Naeimi S, Vahabzadeh H, Amini M, Soleymani S, Nikmanesh B, Kashi L, Jahanifar Kh, Samie MH, Nematdoust Kh, Hashemi Nasab AA, Daneshi MM, Kazemi MH, Izadi Jahan Parvar R, Dashti E, Rasouli M, Bahmani Sh: Current epidemiology of *Sporozoan* protozoa and frequency of other parasitic entropathogens among people with gastroenteritis in Iran. *Iranian Journal for Parasitology*, 2010; 5(S1): p42.

18. Mohajery M, Shamsian SA, Mokhtari M, **Nahrevanian H**, Yazdanpanah MJ, Bidkhorji H, Shahi M, Fathimoghadam F, **Nahrevanian H**, Omidinia E, Farahmand M, Khalili G, Hosseini Z, Soleymani S: Comparison of the Th1 and Th2 responses of nonhealing & healing patients with cutaneous leishmaniasis in Mashhad during 2008. *Iranian Journal for Parasitology*, 2010; 5(S1): p49.
19. Jafary SP, **Nahrevanian H**, Omidinia E, Farahmand M, Khalili G, Hosseini Z, Soleymani S: Immunobiochemical evaluation of killed leishmania vaccine (KLV) and BCG adjuvant in inhibition of visceralization of *Leishmania major* in Balb/c mice. *Iranian Journal for Parasitology*, 2010; 5(S1): p54.
20. Salehizadeh E, **Nahrevanian H**, Farahmand M, Hajihosseini R, Alimohammadian MH, Saghir R, Khalili G, Naeimi S: *In vivo* investigation of Killed Leishmania Vaccine's (KLV) efficacy with Imiquimod (IMQ) as adjuvant in inhibition of visceralization of *L. major* in Balb/c model. *Iranian Journal for Parasitology*, 2010; 5(S1): p68.
21. Abofazeli F, **Nahrevanian H**, Kazemi M, Hajihosseini R, Naeimi S: Pharmacological and biochemical evaluation on antimalarial effects of *Artemisia turanica* on *Plasmodium berghei* in vivo. *Iranian Journal for Parasitology*, 2010; 5(S1): p74.
22. Sheykhkanlooye Milan B, **Nahrevanian H**, Kazemi M, Hajihosseini R, Soleymani S: Pharmacochimistry on natural components of Iranian flora *Artemisia sieberi* and its antimalarial effects on *Plasmodium berghei* in vivo. *Iranian Journal for Parasitology*, 2010; 5(S1): p78.
23. Farahmand M, Atashi Shirazi H, **Nahrevanian H**: A2 gene among isolates from Iranian cutaneous leishmania species is highly conserved gene. *International Journal of Infectious Diseases*, 2010; 14(S2): PP-201, S86.
24. **Nahrevanian H**, Jalalian M, Farahmand M, Esmaeili Rastaghi AR: Systemic leishmaniasis are inhibited by acetylsalicylic acid via nitric oxide pathway in *Leishmania major* infected susceptible Balb/c mice. *International Journal of Infectious Diseases*, 2010; 14(S2): PL-008, S16.
25. **Nahrevanian H**, Jalalian M, Farahmand M, Esmaeili Rastaghi AR, Assmar M, Sayyah M, Amini M: Acetyl salicylic acid inhibits systemic leishmaniasis via nitric oxide pathway in susceptible Balb/c model infected with *Leishmania major*. *Nitric Oxide, Biology & Chemistry*, 2010; 22 (Suppl1): P150, S89.
26. Sadeghi Tafreshi AR, Zamani Z, **Nahrevanian H**, Arjmand M, Lame-Rad B, Sadeghi S, Poorfallah F: Study of glutathione-s-transferase enzyme activity in rodent and human malaria (*Plasmodium berghei* & *Plasmodium falciparum*), *Journal of The Iranian Chemical Society*, 2009; 6(S1): P-10-172-1, S24.
27. Davachi S, Ghasemi F, **Nahrevanian H**, Hajihosseini R, Amini M, Omidinia E: Immunobiochemistry of nitric oxide, microelements and liver enzymes and inhibitory evaluation of visceralization in *Leishmania major* infected Balb/c mice under treatment with Paromomycin, *Journal of The Iranian Chemical Society*, 2009; 6(S1): P-10-177-1, S28.
28. Ghasemi F, Davachi S, **Nahrevanian H**, Amini M, Hajihosseini R: Anti-leishmanial effects of L-arginine as nitric oxide inducer and Indomethacin as prostaglandin inhibitor in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER, *Journal of The Iranian Chemical Society*, 2009; 6(S1): P-10-201-1, S28-29.
29. Esmaeili B, **Nahrevanian H**, Kazemi M, Nazem H, Amini M: Biochemical evaluation of anti-malarial effects of *Artemisia khorassanica* extracts in vivo in murine malaria, *Journal of The Iranian Chemical Society*, 2009; 6(S1): P-10-151-1, S119.
30. Farahmand M, **Nahrevanian H**, Atashi Shirazi H, Naderi S: Molecular genetics of A₂ proteins analysis from Iranian *Leishmania* species, *Journal of The Iranian Chemical Society*, 2009; 6(S1): P-10-586-1, S209.
31. **Nahrevanian H**: Leishmaniasis as a neglected tropical disease in the world, Eastern Mediterranean Region and Iran, *International Journal of Infectious Diseases*, 2009; 13(S1): CS6-01, S9.
32. **Nahrevanian H**, Eskandar Omidinia, Davachi S, Farahmand M, Amini M: Anti-leishmanial effects of paromomycin in both cutaneous and visceral forms of *Leishmania major* infection in Balb/c mice, *International Journal of Infectious Diseases*, 2009; 13(S1): PP-167, S94.

33. **Nahrevanian H**, Farahmand M, Amini M, M Arjmand, R Hajihosseini, F Ghasemi: Immunotherapy of cutaneous leishmaniasis by inhibition of prostaglandin and induction of nitric oxide in susceptible Balb/c infected with *Leishmania major*, *International Journal of Infectious Diseases*, 2009; 13(S1): PP-168, S94.
34. **Nahrevanian H**, Kazemi M, Esmaeili B, Nazem H, Amini M, Naeimi S: Anti-malarial effects of Iranian flora *Artemisia khorassanica* on experimental *Plasmodium berghei* infection and analysis of its pharmacochimistry, *International Journal of Infectious Diseases*, 2009; 13(S1): PP-169, S94.
35. Sharif M, Daryani A, Nasrolahei M, **Nahrevanian H**, Rostami M: Evaluation of anti-leishmanial efficacy by *in vivo* administration of herbal extract *Artemisia auchery* on *Leishmania major* in Balb/c mice, *International Journal of Antimicrobial Agents*, 2009; 34(S2): P250, S105.
36. Farahmand M, Atashi Shirazi H, **Nahrevanian H**: Molecular survey of A2 proteins in leishmania species from endemic areas in Iran, *Tropical Medicine and International Health*, 2009; 14(S1): 182-183.
37. Rustaiyan A, **Nahrevanian H**, Kazemi M: Tehranolide, A sesquiterpene lactone with an endoperoxide group that probably has the same effect as the antimalarial agent Artemisinin, *Planta Medica*, 2009; 75(9): 944.
38. Sadeghi Tafreshi AR, Zamani Z, **Nahrevanian H**, Arjmand M, Sadeghi S, Lame-Rad B, Pourfallah F: Study of Gluthatione-S-transferase enzyme activity in rodent and human malaria (*Plasmodium berghei* and *Plasmodium falciparum*). *Clinical Chemistry and Laboratory Medicine*, 2009; 47(402): p S248-S256.
39. **Nahrevanian H**, Najafzadeh M, Farahmand M, Zamani Z, Hajihosseini R: Immunobiochemical evaluation of antileishmanial effects of trinitroglycerin as nitric oxide donor in BALB/C mice infected with *Leishmania major* MRHO/IR/75/ER. *Nitric Oxide, Biology & Chemistry*, 2008; 19(Suppl1): p62.
40. **Nahrevanian H**, Esmaeilnejad S, Khatami Sh, Hajihosseini R, Aghighi Z, Javadian S: Antimalarial effects of nitric oxide synthetic metabolite (S-nitrate) as a novel therapy for *in vivo* treatment of *Plasmodium berghei* NY. *Nitric Oxide, Biology & Chemistry*, 2008; 19(Suppl1): p68.
41. Mohajeri M, Shamsian SAA, Mahmoudi M, **Nahrevanian H**, Yazdanpanah SMJ, Shahi M: The role of IL-10 and IFN- γ in resistance and sensitive patients under treatment with Glucantime in Mash had. *Iranian J Prasitology*, 2008; 3(1) Suppl1: p27.
42. **Nahrevanian H**, Ghasemi F, Amini M, Farahmand M, Arjmand M, Hajihosaini R: Immunobiochemical evaluation of prostaglandin and nitric oxide in the physiopathology of Balb/c mice infected with *Leishmania major*. *Iranian J Prasitology*, 2008; 3(1) Suppl1: p59.
43. Amini M, **Nahrevanian H**, Khatami S, Farahmand M, Javadian S, Nahrevanian S: Evaluation of immunobiochemical responses of sensitive Balb/c and resistant C57bl/6 mice infected with *Leishmania major* MRHO/IR/78/ER. *Iranian J Prasitology*, 2008; 3(1) Suppl1: p73.
44. Najafzadeh M, **Nahrevanian H**, Hajihosaini R, Zamani Z, Javadian S, Fayaz S, Fatemi N: Effects of trinitroglycerin therapy on serum zinc and copper, and liver enzymes in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER. *Archives of Iranian Medicine*, 2007; 10(4) Suppl1: S18.
45. Amini M, **Nahrevanian H**, Khatami S, Farahmand M, Javadian S, Fayaz S, Mirkhani F: Biochemical evaluation of trace elements and liver enzymes during *Leishmania major* infection in susceptible Balb/c and resistant C57bl/6 mice. *Archives of Iranian Medicine*, 2007; 10(4) Suppl1: S60.
46. Rustaiyan A, **Nahrevanian H**, Kazemi M, Larijani K: A new antimalarial agent; effects of extracts of *Artemisia diffusa* against *Plasmodium berghei*, *Planta Medica*, 2007; 73(9): 892.
47. Ahmadi A, Sayyah M, **Nahrevanian H**, Haeri Rohani A: Lipopolysaccharide inhibits amygdala-kindled seizures in rats, *European Journal of Neurology*, 2007; 14(S1): 81.
48. Farahmand M, **Nahrevanian H**, Assmar M, Mohebbali M, Zarei Z: Identification of A2 proteinsin *Leishmania infantum* from canine isolates of Meshkinshahr, northwestern Iran, *Tropical Medicine and International Health*, 2007; 12(S1): 255.

49. **Nahrevanian H**: The key role for nitric oxide as a free radical in cerebral malaria. *Iranian Journal of Immunology*, 2004; (S): 118.
50. **Nahrevanian H**, Assmar M, Ghorbani S M: Cryptosporidiosis among patients with acquired immunodeficiency in the Great Tehran. *Journal of the Communicable Diseases*, 2004; 3(3): 26.
51. Assmar M, Raeisi A, Arshi SH, Razavi M, Naddaf SR, **Nahrevanian H**, Hovanesian A, Farahmand M, Ranjbar M: The epidemiology of urban malaria in Parsabad-e-Moghan, Iran. *International Journal of Antimicrobial Agents*, 2004; 24(S2): 509/88p; S175.
52. **Nahrevanian H**, Gholizadeh S J, Farahmand M, Abolhassani M, Assmar M: Investigation on nitric oxide induction as a novel immunological target in malaria infected patients from endemic areas of Iran. *International Journal of Antimicrobial Agents*, 2004; 24(S2): 512/88p; S176.
53. Assmar M, Terhovanessian A, Yasaii F, Esmaeili AR, **Nahrevanian H**, Farzaneh Nejhad Z: Detection of congenital toxoplasmosis by Nested-PCR in Iran, *Acta Tropica*, 2002; 83(S1): P079.
54. Dascombe MJ, **Nahrevanian H**: Pharmacological assessment of the role of nitric oxide in mouse models of malaria *in vitro*, *Proceedings, Australian Physiological Society*, 2001; 32(S2): 20.
55. **Nahrevanian H**, Pickering-Brown S, Owen F, Dascombe MJ: Induction of nitric oxide synthase 2 (iNOS) mRNA in target organs of murine malaria. *Biochemical Society Transactions*, 2000; 28 (5): A482.
56. **Nahrevanian H**, Assmar M: The first cases of cryptosporidiosis & Isosporiasis among AIDS patients in Iran, *Journal of Parassitologia*. 1996; 38(1,2): 418.

Gene & Protein Submission to NCBI GenBank

- 2013 GenBank: [KF422681.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422681.1) Plasmodium vivax isolate ires46 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422680.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422680.1) Plasmodium vivax isolate ires45 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422679.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422679.1) Plasmodium vivax isolate ires44 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422678.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422678.1) Plasmodium vivax isolate ires43 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422677.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422677.1) Plasmodium vivax isolate ires42 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422676.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422676.1) Plasmodium vivax isolate ires41 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422675.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422675.1) Plasmodium vivax isolate ires40 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422674.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422674.1) Plasmodium vivax isolate ires39 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422673.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422673.1) Plasmodium vivax isolate ires38 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013 GenBank: [KF422672.1](http://www.ncbi.nlm.nih.gov/nuccore/KF422672.1) Plasmodium vivax isolate ires37 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>

- 2013** GenBank: [KF422671.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422671.1) Plasmodium vivax isolate ires36 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422670.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422670.1) Plasmodium vivax isolate ires35 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422669.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422669.1) Plasmodium vivax isolate ires34 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422668.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422668.1) Plasmodium vivax isolate ires33 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422667.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422667.1) Plasmodium vivax isolate ires32 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422666.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422666.1) Plasmodium vivax isolate ires31 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422665.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422665.1) Plasmodium vivax isolate ires30 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422664.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422664.1) Plasmodium vivax isolate ires29 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422663.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422663.1) Plasmodium vivax isolate ires28 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422662.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422662.1) Plasmodium vivax isolate ires27 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422661.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422661.1) Plasmodium vivax isolate ires26 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422660.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422660.1) Plasmodium vivax isolate ires25 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422659.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422659.1) Plasmodium vivax isolate ires24 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422658.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422658.1) Plasmodium vivax isolate ires23 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422657.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422657.1) Plasmodium vivax isolate ires22 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422656.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422656.1) Plasmodium vivax isolate ires21 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422655.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422655.1) Plasmodium vivax isolate ires20 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422654.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422654.1) Plasmodium vivax isolate ires19 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422653.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422653.1) Plasmodium vivax isolate ires18 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>

- 2013** GenBank: [KF422652.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422652.1) Plasmodium vivax isolate ires17 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422651.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422651.1) Plasmodium vivax isolate ires16 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422650.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422650.1) Plasmodium vivax isolate ires15 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422649.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422649.1) Plasmodium vivax isolate ires14 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422648.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422648.1) Plasmodium vivax isolate ires13 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422647.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422647.1) Plasmodium vivax isolate ires12 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422646.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422646.1) Plasmodium vivax isolate ires11 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422645.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422645.1) Plasmodium vivax isolate ires10 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422644.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422644.1) Plasmodium vivax isolate ires9 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422643.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422643.1) Plasmodium vivax isolate ires8 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422642.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422642.1) Plasmodium vivax isolate ires7 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422641.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422641.1) Plasmodium vivax isolate ires6 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422640.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422640.1) Plasmodium vivax isolate ires5 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422639.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422639.1) Plasmodium vivax isolate ires4 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422638.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422638.1) Plasmodium vivax isolate ires3 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422637.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422637.1) Plasmodium vivax isolate ires2 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2013** GenBank: [KF422636.1](https://www.ncbi.nlm.nih.gov/nuccore/KF422636.1) Plasmodium vivax isolate ires1 apical membrane antigen 1 (AMA-1) gene, partial cds, <http://www.ncbi.nlm.nih.gov/nuccore/?term=nahrevanian>
- 2010**, GenBank: GU451261.1 (Nucleotide) Mus musculus strain MF1 nitric oxide synthase 2 (Nos2) mRNA, partial cds. <http://preview.ncbi.nlm.nih.gov/nuccore/290465640>
- 2010**, GenBank: ADD25171.1 (Protein) nitric oxide synthase 2 [Mus musculus]. <http://preview.ncbi.nlm.nih.gov/protein/290465641>

- 2010**, GenBank: GU376735.1 (Nucleotide) *Leishmania tropica* strain MHOM/IR/09/Mash-F stage-specific S antigen-like protein (A2) gene, complete cds.
<http://preview.ncbi.nlm.nih.gov/nuccore/288551599>
- 2010**, GenBank: ADC53298.1 (Protein) Stage-specific S antigen-like protein [*Leishmania tropica*].
<http://preview.ncbi.nlm.nih.gov/protein/288551600>
- 2009**, GenBank: GU235991.1 (Nucleotide) *Leishmania major* strain MRHO/IR/75/ER stage-specific S antigen-like protein (A2) gene, complete cds.
<http://preview.ncbi.nlm.nih.gov/nuccore/281490069>
- 2009**, GenBank: ADA71542.1 (Protein) Stage-specific S antigen-like protein [*Leishmania major*].
<http://preview.ncbi.nlm.nih.gov/protein/281490070>

Honours, Awards & Bursaries

- 2011, Travel Grant**, (Euros 1,000), 19th United European Gastroenterology Week (19th UEGW), October 22-26, Stockholm, Sweden.
- 2010, Travel Award**, (JY 30,000), 6th International Conference on the Biology, Chemistry & Therapeutic Applications of Nitric Oxide, Kyoto, Japan.
- 2009, AGD Prize**, as Shortlisted abstracts (RMB 1,000), 3rd Ditan International Conference on Infectious Diseases, Beijing, China.
- 2008-10, Project grant**, (USD 10,000) for project No. 353, Centre for Diseases Control of MOHME.
- 2006-10, Co-Projects grants**, for projects Parand Islamic Azad University, Mash-had UMS (No. 86780), Tehran UMS, Ahvaz UMS.
- 2003-12, Projects grants**, for projects numbers 200, 212, 237, 308, 318, 352, 353, 451, 584, 613 Pasteur Institute of Iran, Tehran, Iran.
- 1996-2000, Full scholarship** to study for a PhD degree in Molecular Parasitology at the University of Manchester, awarded by Iran Ministry of Health and Medical Education.
- 1986-2010, Co-Projects grants**, for projects numbers 1, 2, 49, 81, 220, 229, 368, 388, 394, 434, Pasteur Institute of Iran, Tehran, Iran.

PROJECTS *Principal investigator (PI), Co- investigator (Co-I)*

Fanavary Project **Kashan project**

- 2014-16**, Study on association between splenectomy and nitric oxide production and its role in the immunoparasitology of rodent malaria caused by *Plasmodium berghei*, Co-project by Department of Parasitology, Pasteur Institute of Iran & Kashan University of Medical Sciences. (Co-I). Project No. 93140 KUMS, Accepted in PII Research Council No. 594.
- 2014-16**, Studies on synergistic effects of eosin-B with sulphadoxine–pyrimethamine or artemisinin on malaria parasites (*Plasmodium falciparum* and *Plasmodium berghei*) *in vitro* and *in vivo* by observation of their metabolic patterns using 1HNMR, Departments of Parasitology & Biochemistry, Pasteur Institute of Iran (Co-I). Project No. 746.
- 2014-16**, A study on infection of rodents to *Leptospira* spp. in three northern provinces of Iran by microscopic agglutination test (MAT) and nested-PCR in order to determine the prevalent serovars, Departments of Parasitology, Bacteriology & Epidemiology, Pasteur Institute of Iran (PI). Project No. 739.
- 2014-16**, Study of potency of primaquine loaded chitosan nanoparticles for the malaria treatment, Eastern Mediterranean Genomics & Health Biotechnology (EMGEN) Co-project by Department of Parasitology, Pasteur Institute of Iran & Iranian Research Organization for Science and Technology (IROST) (Co-I). Project No. 20141.

- 2012-14**, A comparison on seroepidemiological study of visceral leishmaniasis in non-stray dogs of Meshkinshahr, Ardabil province by three ELISA, rK39 and DAT assays, Department of Parasitology, Tehran University of Medical Sciences & Pasteur Institute of Iran (PI). Project No. 613.
- 2012-14**, Immuno-parasitological effects of different drug forms of L-arginine as nitric oxide precursor for *in vivo* treatment of cutaneous leishmaniasis caused by *Leishmania major*, Department of Parasitology, Pasteur Institute of Iran (PI). Project No. 584.
- 2012-13**, Comparison of antimalarial activity of different species of Iranian *Artemisia* flora on *Plasmodium berghei* in mouse model, Islamic Azad University of Takestan, (Co-I).
- 2011-12**, Evaluation of anti-leishmanial efficacy of G2 as an adjuvant by *in vivo* administration in Balb/c mice infected by *Leishmania major*, Golestan University of Medical Sciences, (Co-I). Project agreement in Commission No. 491.
- 2010-11**, The effects of supplementary L-Arginine dietary on serum nitric oxide concentration in the male bodybuilders, Islamic Azad University, Parand Center, Sports Group (Co-I). Project agreement in Commission No. 487.
- 2009-11**, Evaluation of immuno-parasitologic role and activity of Treg cells in cutaneous leishmaniasis, Mash-had University of Medical Sciences, Parasitology Group (Co-I). Project No. 86780.
- 2009- 11**, Study on the protective effects of Ghrelin on liver injuries due to Acetaminophen in male rats, Tehran University of Medical Sciences, Physiology Group (Co-I).
- 2009-11**, Investigation on immunopharmacological effects of acetyl salysilic acid (ASA) and its antioxidant role *via* nitric oxide (NO) pathway on Balb/c mice infected with *Leishmania major* Department of Parasitology, Pasteur Institute of Iran (PI). Project No. 451.
- 2009-11**, Genetic analysis of the apical membrane antigen-1 (AMA-1) as a vaccine candidate in *Plasmodium vivax* isolates from endemic areas of Iran (2009-10), Department of Parasitology, Pasteur Institute of Iran (Co-I). Project No. 434.
- 2008-10**, Genetic analysis of A2 protein in *L. infantum* & *L. major* in endemic areas of Iran, Department of Parasitology, Pasteur Institute of Iran (Co-I). Project No. 394.
- 2008-11**, Cloning and expression of human Tissue Plasminogen Activator (tPA) gene in CHO, *E. coli* and transgenic mice for semi-industrial production of recombinant tPA protein, Medical Biotechnology Network of IR Iran (Co-I). Project No. 388.
- 2008- 10**, A study on the prevalence of Sporozoan protozoa and other parasitic enteropathogens in the gastroenteritic patients refering to the central laboratories in ten provinces of Iran, A national project collaboration between Pasteur Institute of Iran and Centre for Diseases Control of MOHME (PI). Project No. 353.
- 2008-09**, Study the prevalence of Giardiasis in primary school children at the age of 6-12 years and determination of serum Iron, Zinc and Cupper level in Imam Khomeini port 2006, Ahvaz UMS (Co-I).
- 2008-09**, Immunobiochemistry of nitric oxide, microelements and liver enzymes and inhibitory evaluation of visceralization in *Leishmania major* infected Balb/c mice under treatment with Paromomycin, Payame Nour University, Tehran Center Unit (PI).
- 2007-08**, Study on the effects of liver cirrhosis and cholestase on basis secretion and stimulation on stomach acid & pepsin in rats, Tehran University of Medical Sciences, Physiology Group (Co-I).
- 2007-08**, A comparison of Glutathione-s transferase in human and rodent malaria in response to antimalarial agents like eosin B, artemisine & chloroquine. Department of Biochemistry, PII, (Co-I). Project No. 368.
- 2007-08**, Immuno-parasitological evaluation of prostaglandin (PG) inhibition and nitric oxide (NO) induction in susceptible Balb/c mice infected with *Leishmania major* (PI). Project No. 352.
- 2007-09**, Inoculation of *Cryptosporidium* parasite into immunosuppressed animals for isolation of endemic strains and evaluation of antigenic proteins (PI). Project No. 308.

- 2006-08**, Immuno-biochemical evaluation of TNG as a nitric oxide releasing drug and its antiparasitic role in Balb/c mice infected with *Leishmania major* (PI). Project No. 318.
- 2006-07**, Immuno-biochemical evaluation of efficacy by nitric oxide synthetic metabolites on malaria caused by *Plasmodium berghei* in animal model (PI).
- 2006-07**, Isolation & purification of two peroxide combination *Artemisinin* & *Tehranolid* with antimalarial effects from *Artemisia annua* & *Artemisia diffusa* in bench scale; evaluation of natural composition of *Artemisia* species (Co-I).
- 2006-07**, Immuno-biochemical comparison of nitric oxide or RNI production in susceptible Balb/c and resistant C57bl/6 mice infected with *Leishmania major* (PI).
- 2006-07**, Evaluation of Th1 & Th2 cytokines in healing and nonhealing cases of cutaneous leishmaniasis treated with Glucantime in Mashhad in 1385 (Co-I).
- 2006-07**, In vivo evaluation of antileishmanial activity of *Artemisia auckery* on *Leishmania major* (Co-I).
- 2006-07**, Evaluation of the effect of intrahippocampal injection of bacterial endotoxin (LPS) on seizure acquisition in kindling model of epilepsy in rats, Department of Physiology & Pharmacology, Pasteur Institute of Iran, (Co-I). Project No. 220.
- 2005-07**, A study on the prevalence rate of *Cryptosporidiosis* and *Isosporiasis* in patients with gastroenteritis and its comparison with other parasitic agents in Mazandaran province, North of Iran, Department of Parasitology, Research Centre of Amol. Pasteur Institute of Iran, (PI).
- 2005-06**, An investigation on A2 proteins from cultured amastigotes and promastigotes of *Leishmania infantum* from endemic areas of Iran and comparison with those in *L donovani* & *L chagasi*, Department of Parasitology, Pasteur Institute of Iran (Co-I). Project No. 229.
- 2004- 06**, The evaluation of anti-leishmanial activity of *in vivo* administration of selective nitric oxide inducer and nitric oxide donor on *Leishmania major* in animal model, Department of Parasitology, Pasteur Institute of Iran, (PI). Project No. 212.
- 2003-05**, Investigation on nitric oxide (NO) levels as a novel immunological target in malaria infected patients in Iran, Department of Parasitology, Pasteur Institute of Iran, (PI). Project No. 200.
- 2001**, Western blot analysis of iNOS enzyme expression in target organs of murine malaria, The University of Manchester, UK, (PI).
- 2001**, Application of NO inducers and NO donors in the treatment of lethal *P berghei* malaria, The University of Manchester, UK, (PI).
- 2000**, The effects of NOS-inhibition in patho-physiology of *P c chabaudi* infected mice, The University of Manchester, UK, (PI).
- 2000**, *In vitro* direct detection of NO production by electrochemical assay in the target organs of *P berghei* and *P c chabaudi* infected mice, The University of Manchester, UK.
- 2000**, RT-PCR analysis of iNOS mRNA induction in target organs of *P berghei* and *P c chabaudi* infected mice in compare to NO and RNI production, The University of Manchester, UK, (PI).
- 1999**, Study on the malaria parasite strains versus host species, *P berghei* as lethal and *P c chabaudi* as non-lethal strains versus MF1 as outbreed and C57BL/6, as inbreed species of mice, The University of Manchester, UK, (PI).
- 1999**, Flow cytometry analysis of WBC populations in the spleen of *P berghei* infected mice and responsibility of these cells for NO production, The University of Manchester, UK, (PI).
- 1999**. Identification of site(s) of NO production in target organs of murine malaria (*P berghei* and *P c chabaudi*), The University of Manchester, UK, (PI).
- 1999**, The involvement of NO in terminal anaesthetised *P berghei* infected mice by *in situ* direct detection of endogenous NO in the brain using a sensitive electrochemical probe, The University of Manchester, UK, (PI).

- 1998**, Measurement of total nitrite level inside the parasitised red blood cells (PRBC) and uninfected red blood cells (URBC) compare with that in outside the cells, The University of Manchester, UK, (PI).
- 1998**, Investigation in the synergetic effects of LPS with malaria to induce nitric oxide (NO) production and comparison of the NO induction by bacterial and parasitic endotoxins, The University of Manchester, UK, (PI).
- 1998**, The involvement of reactive nitrogen intermediates (RNI) in the pathology of inbred and outbred mice infected with *P. berghei* and *P. c. chabaudi*, The University of Manchester, UK, (PI).
- 1996**, The survey on immunogenicity of irradiated *Toxoplasma gondii* in animal model, Department of Parasitology, Pasteur Institute of Iran, (Co-I). Project No. 81.
- 1995**, A study of prevalence rate of intestinal parasites among children in Mazandaran province (northern Iran), Department of Parasitology, Pasteur Institute of Iran, (Co-I). Project No. 49.
- 1994**, A survey in effect metronidazole, alluporinol and niphedepine and comparison with glucantime in treatment of *Leishmania major* *in vitro*, Department of Parasitology, Pasteur Institute of Iran, (Co-I).
- 1992**, A study on Cryptosporidiosis in patients with acquired immunodeficiency of ten hospitals in Tehran. Iran, Tehran University of Medical Sciences & Pasteur Institute of Iran, (PI).
- 1990**, Study on *Toxoplasma gondii* Penetration Enhancing Factor (PEF) in animal model, Department of Parasitology, Pasteur Institute of Iran, (Co-I). Project No. 2.
- 1988**, Preparation of parasitological training slides from protozoa & helminths, Department of Parasitology, Pasteur Institute of Iran, (PI).
- 1986**, An investigation in the role of parasitic pathogens in children diarrhoea in Tehran, Department of Parasitology, Pasteur Institute of Iran, (Co-I). Project No. 1.

COLLABORATION WITH WORKSHOPS, CONGRESS & TRAINING COURSES

2015 Toxoplasmosis

2015 Trichomoniasis

- 2008**, Workshop on The Sporozoan protozoa and comparison with other parasitic enteropathogens, 23 Ordibehesht 1387 (11 May 2008), Pasteur Institute of Iran, Tehran, Iran.
- 2007**, Workshop on Application of Geographic Information System (GIS) in Medical Sciences, 16 Esfand 1385 (7 March 2007), Pasteur Institute of Iran, Tehran, Iran.
- 2006**, Workshop on Microbiology (Parasitology), 28 Ordibehesht 1385 (20 April 2006), Iranian Scientific Association of Pathology, Tehran, Iran.
- 2005**, Workshop on Microsatellite Analysis & SSCP Based Mutation Screening, 12 & 13 Mehr 1384 (4-5 Oct. 2005), Pasteur Institute of Iran, Tehran, Iran.
- 2005**, Workshop on The role of Cryptosporidiosis & Isosporiasis in Gastroenteritis, 3 & 4 Khordad 1384 (25-26 May 2005), North Research Centre of Pasteur Institute of Iran, Amol, Iran.
- 2002**, Workshop on Updates in Malaria, 25 Ordibehesht 1381 (15 May 2002), Pasteur Institute of Iran, Tehran, Iran.
- 1994**, Congress of Blood and Related Diseases, 5-7 Mehr 1373 (27-29 Sept. 1994), Blood Transfusion Center, Tehran, Iran.
- 1991**, The First Congress on Biochemistry, 28-30 Ordibehesht 1370 (18-20 May 1991), Tarbiat Modarres University, Tehran, Iran.

TRAINING COURSES & WORKSHOPS ATTENDED

- 2010**, The Course on Strategic Planning, 26 Mordad 1389 (17 August), Pasteur Institute of Iran, Tajrish, Iran.

- 2008**, *The 1st Workshop on Application of Bio-safety in Biotechnology*, 4 Ordibehesht 1387 (24 April), Pasteur Institute of Iran, Tehran, Iran.
- 2007**, *The 1st Workshop on Laws, benefits of inventor in development of biotechnology*, 19 Ordibehesht 1386 (9 May 2007), Pasteur Institute of Iran, Tehran, Iran.
- 2007**, *Workshop on Application of Geographic Information System (GIS) in medical sciences*, 16 Esfand 1385 (7 March 2007), Pasteur Institute of Iran, Tehran, Iran.
- 2006**, *The 1st Workshop on Patent in Biotechnology in Iran*, 31 Farvardin 1385 (20 April 2006), Pasteur Institute of Iran, Tehran, Iran.
- 2005**, *Workshop on Microsatellite Analysis & SSCP Based Mutation Screening*, 12-13 Mehr 1384 (4-5 Oct. 2005), Pasteur Institute of Iran, Tehran, Iran.
- 2005**, *The First Joint Workshop on Laser Micro-dissection*, 4-5 Tir 1384 (25-26 June 2005), Cancer research Center (CRC), Cancer Institute of I. R. Iran, Tehran, Iran.
- 2004**, *The 3rd International Training Course on Tropical Diseases Control (ITCTDC)*, 1 Sept.-31 Oct. 2004, Jiangsu Institute of Parasitic Diseases (JIPD), Wuxi, Jiangsu Province, China.
- 1998-2000**, Involving in training courses including: molecular parasitology, immunoparasitology, clinical immunology, immunological methods, flow cytometry & cell sorting, DNA sequencing, PCR for beginner, DNA transfection into mammalian cells, purification & characterization of proteins & glycoproteins, animal cell & tissue culture, patch clamp methods, animals scientific procedures, control of substances hazardous to health (COSHH), light and electron microscopy, computing, data handling & statistic, bioinformatics, planning & communication in research, personal transferable skills, professional research skills and communication skills, School of Biological Sciences, Medical faculty, The University of Manchester, Manchester, UK.
- 1994**, *A workshop on serological methods in diagnosis of parasitic diseases*, Pasteur Institute of Iran, Tehran, Iran.
- 1992**, *Primary Health Care (PHC)*, Ahvaz public health centre, Khouzestan Province, Iran.
- 1991**, *Protozoology & Helminthology courses*, Department of Parasitology, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.

STUDENT THESIS

Supervisor (S), Advisor (A)

2015-17, Roya Jalilpour, PharmMed in Pharmacology, Islamic Azad University, Pharma Sciences of Tehran Unit, Esmaeili AR (S), **Nahrevanian H (A)**: xxxxxxxxxxxxxxxxxxxxx

2015-18, Moslem Papizadeh, PhD by Research, Pasteur Institute of Iran, Pourshafia MR (S), **Nahrevanian H (S)**, XXXX X (A): Probiotic xxxxxxxxxxxxxxxx

2014-17, Soheila Shirmohammadi, MSc in Biochemistry, Islamic Azad University, Unit Shiraz. **Nahrevanian H (S)**, Razmi N (A): Development and assessment of Colorimetric assay kit for detection of nitric oxide

2014-15, Mehrnoush Modaressi nejhad, MSc in Biochemistry, Islamic Azad University, Unit Damghan. **Nahrevanian H (S)**, Khatami S (A), XXXX X (A): Immunobiochemical study of host during malaria via modulation of immune system and its effects on nitric oxide and microelements in animal model

2014-15, Esmat Bagheri, MSc in Biochemistry, Islamic Azad University, Unit Damghan. **Nahrevanian H (S)**, Khatami S (A), XXXX X (A): Immunobiochemical evaluation of L-Arginine as nitric oxide precursor and its antimalarial role in NMRI mice infected by Plasmodium berghei

2013-14, Sanaz Naderi, MSc in Microbiology, Islamic Azad University, Sciences & Research Unit Kordestan. **Nahrevanian H** (S), Khalaj V (A): Survey of Cloning, expression and purification of recombinant A₂ protein from *Leishmania infantum* for diagnosis of visceral leishmaniasis

2012-14, Reza Asadi Eisa kan, PhD in Parasitology, Veterinary Faculty, Islamic Azad University, Sciences & Research Tehran Unit. Rahbari S (S), Valadkhani Z (S), Houghoughi N (A), **Nahrevanian H** (A): Giardia assemblage of human and animal population in Urmia city

2014-16, Sara Soleymani, MSc in Medical Parasitology, Kashan University of Medical Sciences, **Nahrevanian H** (S), Arbabi GR (S), Esmaeili AR (A): Study on association between splenectomy and nitric oxide production and its role in the immunoparasitology of rodent malaria caused by *Plasmodium berghei*

2013-14, Moslem Najafi, MSc in Biochemistry, Islamic Azad University, Unit Damghan. **Nahrevanian H** (S), Khatami S (A), XXXX X (A): Immuno-biochemical study of bacterial lipopolysaccharide (LPS) as inducer of the immune system to prevent the development of murine Leishmaniasis caused by *Leishmania major* in Balb/c mice via nitric oxide pathway

2013-14, Padina Ghaffarinejhad, MSc in Microbiology, Islamic Azad University, Sciences & Research Unit Ayatollah Amoli, Amol. **Nahrevanian H** (S), Zaboli F (S), Farahmand M (A): Serological investigation on visceral leishmaniasis in dogs from Meshkin-Shahr district, Ardabil province, using direct agglutination test and rKE16 dipstick

2012-16, Mahin Farahmand, PhD by Research, Pasteur Institute of Iran, **Nahrevanian H** (S), Khalaj V (S), Mohebbi M (A): Design of ELISA and Latex Agglutination methods using rA2 protein from *Leishmania infantum* to diagnose visceral leishmaniasis of human and dog in comparison with standard serological assays including DAT and rKE16 Dipstick

2012-16, Behzad Esfandiari, PhD by Research, Pasteur Institute of Iran, Pourshafia MR (S), **Nahrevanian H** (S), Gooya MM (A), Khaki P (A) Mostafavi E (A), Darvish J (A): Seroepidemiological and molecular study of rodents in three northern provinces in accordance to infection with Leptospirosis by microbial culture, microscopic agglutination test (MAT) and polymerase chain reaction (Nested-PCR)

2012-13, Shabnam Khodadadi, PharmMed in Pharmacology, Islamic Azad University, Pharma Sciences of Tehran Unit, **Nahrevanian H** (S), Esmaeili AR (S), Kazemi M (A), Bagheri Bajstani F (A): The study on pharmacological effects of Iranian flora *Artemisia sieberi* extract against acute toxoplasmosis in vivo

2012-13, Shahrzad Nahrevanian, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Khatami Sh (S), Hajhossein R (A): Design, construction and nationalization of Colorimetric assay for measuring nitric oxide values in biological fluids and tissue samples by detection of stable metabolites

2011-12, Sepideh Farahani, PharmMed in Pharmacology, Islamic Azad University, Pharma Sciences of Tehran Unit, Esmaeili AR (S), **Nahrevanian H** (S), Kazemi M (A), Bagheri Bajstani F (A): The study of antiparasitic activity of *Artemisia turanica* (an Iranian flora) against acute toxoplasmosis in animal model

2011-12, Fatemeh Faezi, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Bidaki SK (S), Sayyah M (A): Immuno-parasitological effects of different types of L-arginine as nitric oxide precursor for *in vivo* control of cutaneous leishmaniasis caused by *Leishmania major*

2010-11, Sara Nemati, MSc in Medical Parasitology, Zanzan University of Medical Sciences, **Nahrevanian H** (S), Haniloo A (S), Fazaeli A (A), Farahmand M (A): In vivo and in vitro

investigation on anti-leishmanial efficacy of artemisinin in comparison with glucantim on endemic strain of *Leishmania major*

2011-12, Tooraj Miandoabi, MSc in Medical Parasitology, Urmia University of Medical Sciences, Urmia. **Nahrevanian H (S)**, Hazrati Tapeh Kh (S), Mohammadzadeh H (A), Kazemi M (A): Study on antimalarial effects of *Artemisia oliveriana* as an Iranian flora on *Plasmodium berghei* in vivo

2011-12, Hassan Rahmati, MSc in Microbiology, Islamic Azad University of Zanjan. Esmaeli Rastaghi AR (S), Modiri L (S), Assmar M (A), **Nahrevanian H (A)**: Investigation and comparison between human and animal complement in diagnosis of *Toxoplasma gondii* methylen blue Dye test

2008-12, Roohollah Moloudi, PhD in Medical Physiology, Tehran University of Medical Sciences, Department of Physiology. Nabavizadeh F (S), **Nahrevanian H (A)**, Hassanzadeh G (A): The role of GLP-2 and its underlying mechanisms on acute oesophageal epithelium damage due to gastric acid and pepsin reflux in male rats

2011-12, Soghra Fallahi, MSc in Medical Physiology, Tehran University of Medical Sciences, Department of Physiology. Nabavizadeh F (S), Keshavarz M (S), **Nahrevanian H (A)**, Sadeghipour HR (A): The role of leptin on gastric ulcer due to physical and psychic stress and its underlying mechanisms in male rat

2010-12, Parisa Jafari, MSc in Cellulr & Molecular Biology, Islamic Azad University, Tehran Science & Research Unit, **Nahrevanian H (S)**, Omidinia E (A), Nour Mohammadi Z (A): Immunobiochemistry of killed leishmania vaccine (KLV) with BCG adjuvant in inhibition of visceralization of *Leishmania major* in Balb/c mice

2010-11, Elahe Salehizadeh, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H (S)**, Hajihosseini R (S), Alimohammadian MH (A), Saghiri R (A): Immunobiochemical investigation of killed leishmania vaccine (KLV) with Imiquimod as adjuvant in inhibition of visceralization of *Leishmania major* parasite in Balb/c mice

2009-10, Moharram Mafi, MPH in Diseases Management, Tehran University of Medical Sciences, Institute of Public Health Research. Mahmoudi M (S), **Nahrevanian H (S)**, Eftekhari Ardabili H (A), Zahraei M (A): Study on the frequency of Sporozoan protozoa and other parasitic enteropathogens in gastroenteric patients from referral hospitals of selected seven provinces

2010-11, Bayram Sheikhanloy Milan, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H (S)**, Hajihosseini R (S), Kazemi SM (A): Pharmacology on natural components of Iranian flora *Artemisia sieberi* and its antimalarial effects on *Plasmodium berghei* in vivo

2010-11, Fatemeh Aboufazeli, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H (S)**, Kazemi SM (S), Hajihosseini R (A), Ashnagar A (A): An in vivo study on antimalarial effects of *Artemisia turanica* on *Plasmodium berghei* protozoa by its pharmacological and biochemical evaluation

2009-10, Hassan Sanati, MSc in Veterinary Parasitology, Shahid Bahonar University of Kerman, Faculty of Veterinary, Nouroollahi Fard SR (S), Khalili M (S), **Nahrevanian H (A)**: Detection of antibodies against *Toxoplasma gondii* in cattle of Kerman using modified agglutination test (MAT)

2008-10, Hajar Vahabzadeh, MSc in Microbiology, Islamic Azad University of Lahijan. **Nahrevanian H (S)**, Assmar M, Habibzadeh SM, Daneshi MM (A): Study on the frequency of Sporozoan and other parasitic enteropathogens in gastroenteric patients from referral laboratories of Gilan and Ghazvin provinces during one year

2008-10, Maryam Jalalian, MSc in Microbiology, Islamic Azad University of Lahijan. **Nahrevanian H (S)**, Assmar M, Sayyah M, Esmaeili Rasraghi AR (A): Investigation on immunoparasitological

effects of acetyl salysilic acid (ASA) *via* nitric oxide (NO) and C-Reactive Protein (CRP) pathways on Balb/c mice infected with *Leishmania major*

2007-09, Leila Abedinzadeh, MSc in Biology, University of Mohaghegh Ardabili, Ardabil. **Nahrevanian H** (S), Allah Ghasemi X (S), Esfandiary B (A), Eslamifar A (A): Physiopathology of *Cryptosporidium* protozoa in immunosuppressed Inbred mice

2008-09, Sharareh Davachi, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Omidinia E (S), Hajihosseini R (A): Immunobiochemistry of nitric oxide, microelements and liver enzymes and inhibitory evaluation of visceralization in *Leishmania major* infected Balb/c mice under treatment with Paromomycin

2008-09, Behnaz Esmaeili, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Nazem H (S), Kazemi SM (A): An *in vivo* study on natural components of Iranian flora *Artemisia khorassanica* and pharmacochimistry of its antimalarial effects on *Plasmodium berghei*

2008-09, Alireza Sadeghi Tafreshi, MSc in Biochemistry, University of Payame Nour, Tehran. Zamani Z (S), Lame Rad B (S), **Nahrevanian H** (A), Arjmand M (A): In vivo testing of a new antimalaria drug using glutathione-S-transferase as a drug target

2007-08, Fatemeh Ghasemi, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Hajihosseini R (S), Arjmand M (A): Immuno-biochemical evaluation of prostaglandin (PG) and nitric oxide (NO) roles in physiopathology of susceptible Balb/c mice infected with *Leishmania major*

2007-08, Seyedeh Atena Azarinush, MSc in Microbiology, Islamic Azad University of Zanjan. **Nahrevanian H** (S), Esfandiari B, Amirkhani A, Assmar M (A): Epidemiological study on the *Cryptosporidiosis* and other enteropathogenic parasites in patients with gastroenteritis of western cities of Mazandaran province

2006-07, Mana Najafzadeh Barfroush, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Hajihosseini R (S), Zamani Z (A): Biochemical study on TNG as a nitric oxide (NO) releasing agent and evaluation of reactive nitrogen intermediates (RNI) in Balb/c mice infected with *Leishmania major*.

2006-07, Marzieh Amini, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Khatami S (S): Immuno-biochemical comparison of nitric oxide or RNI production in susceptible Balb/c and resistant C57bl/6 mice infected with *Leishmania major*.

2006-07, Somayeh Esmaeil Nejad, MSc in Biochemistry, University of Payame Nour, Tehran. **Nahrevanian H** (S), Hajihosseini R (S), Khatami S (A): Immuno-biochemical evaluation of efficacy by nitric oxide synthetic metabolites (S-Nitrate) on malaria caused by *Plasmodium berghei* in animal model

2005-07, Masoumeh Rostami, MSc in Medical Parasitology, Mazandaran University of Medical Sciences. Sharif M (S), Ziaei H (A), Khalilian (A), **Nahrevanian H** (A): *In vivo* evaluation of antileishmanial activity of *Artemisia auckery* on *Leishmania major*

2005-07, Azam Soleimanpour, MSc in Medical Parasitology, Mazandaran University of Medical Sciences. **Nahrevanian H** (S), Assmar M, Esfandiari B, Amirkhani A (A): A study on the prevalence rate of *Cryptosporidiosis* and *Isosporiasis* in patients with gastroenteritis in eastern part of Mazandaran province in year 1384

2006-07, Seyyed Masoud Kazemi, PhD in Applied Chemistry, Islamic Azad University of Tehran Shomal. Roustayian AH (S), Taghwaei Ganjali S (A), **Nahrevanian H** (A): Isolation & purification of two peroxide combination *Artemisinin* & *Tehranolid* with antimalarial effects from *Artemisia anuva* & *Artemisia difusa* in bench scale; evaluation of natural compositions of *Artemisia* species

2005-06, Azam Ghorbannia Delavar, MSc in Microbiology, Islamic Azad University of Lahijan. **Nahrevanian H (S)**, Assmar M, Esfandiari B, Amirkhani A (A): A study on the prevalence rate of *Cryptosporidiosis*, *Isosporiasis* and pathogenic parasites in patients with gastroenteritis in two Babol and Babolsar cities

2004-05, Jafar Gholizadeh Salmasi, MSc in Medical Microbiology, Pasteur Institute of Iran. **Nahrevanian H (S)**, Abolhassani M, Assmar M (A): A study on nitric oxide (NO) induction by determination of reactive nitrogen intermediates (RNI) as a novel immunological target in people from malaria endemic areas of Iran

SEMINAR, CONGRESS AND CONFERENCE PROCEEDINGS

NATIONAL CONGRESS

- 1393 (2014)**, A comparative study on diagnostic assays, Polymerase Chain Reaction (PCR), Microscopic Agglutination Test (MAT) and Culture for detection of rodent Leptospirosis in Mazandaran Province, I.R.Iran. *The 15th International Iranian Congress of Microbiology*. 4-6 Shahrivar (26-28 Aug.) Tehran, Iran, O 13, pp.162-163.
- 1392 (2014)**, Diagnosis of visceral leishmaniasis using recombinant A2 protein from *Leishmania infantum*. *The 6th International Iranian Congress Laboratory & Clinics*. 23-25 Bahman (12-14 Feb.) Tehran, Iran, P 80, pp.492.
- 1392 (2014)**, Serological investigation on visceral leishmaniasis in dogs from Meshkin-Shahr district, Ardabil Province, using direct agglutination test (DAT) and rKE16 dipstick. *The 22th Iranian Congress on Infectious Diseases and Tropical Medicine*. 5-9 Bahman (25-29 Jan.) Tehran, Iran, P 13, pp.59.
- 1392 (2014)**, Immunological study of bacterial lipopolysaccharide (LPS) as inducer of the immune system to prevent the development of murine Leishmaniasis caused by *Leishmania major* in Balb/c mice via nitric oxide pathway. *The 22th Iranian Congress on Infectious Diseases and Tropical Medicine*. 5-9 Bahman (25-29 Jan.) Tehran, Iran, P 25, pp.71.
- 1391 (2013)**, Design, construction and nationalization of Colorimetric assay for measuring nitric oxide values in biological fluids and tissue samples by detection of stable metabolites. *The 21th Iranian Congress on Infectious Diseases and Tropical Medicine*. 30 Dey-4 Bahman (19-23 Jan.) Tehran, Iran, P 212, pp.248.
- 1391 (2013)**, Nitric oxide (NO) and C-reactive protein (CRP) involvement in antileishmanial effects of Artemisinin and Glucantim on cutaneous leishmaniasis. *The 21th Iranian Congress on Infectious Diseases and Tropical Medicine*. 30 Dey-4 Bahman (19-23 Jan.) Tehran, Iran, P 233, pp.269.
- 1391 (2013)**, In vivo immuno-parasitological effects of L-arginine on cutaneous leishmaniasis via nitric oxide pathway. *The 21th Iranian Congress on Infectious Diseases and Tropical Medicine*. 30 Dey-4 Bahman (19-23 Jan.) Tehran, Iran, P 212, pp.248.
- 1391 (2012)**, Evaluation of anti-leishmanial effects of Killed *Leishmania* Vaccine with BCG adjuvant in Balb/c infected with *Leishmania major* MRHO/IR/75/ER. *The 1st International and 8th National Congress of Parasitology in Iran (NICOPA 8)*, 25-27 Mehr (16-18 Oct.), KUMS, Kerman, Iran, P-1052; p 54.
- 1391 (2012)**, An experimental trial on immunotherapy of cutaneous Leishmaniasis by modulation of host TH1/TH2 immune responses in Balb/c infected with *Leishmania major* Iranian strain. *The 1st International and 8th National Congress of Parasitology in Iran (NICOPA 8)*, 25-27 Mehr (16-18 Oct.), KUMS, Kerman, Iran, P-1060; p 85.
- 1391 (2012)**, A survey on animal sera as the accessory factor in the diagnosis of *Toxoplasma gondii* with methylen blue Dye test. *The 1st International and 8th National Congress of Parasitology in Iran (NICOPA 8)*, 25-27 Mehr (16-18 Oct.), KUMS, Kerman, Iran, P-2003; p 186.
- 1390 (2011)**, In vivo trial of Artemisinin and its antileishmanial effects on *Leishmania major* in susceptible Balb/c mice in comparison with Glucantim. *The 5th Iranian Congress of Clinical*

Microbiology, 17-19 Aban (8-10 Nov.), Alborzi Microbiology Research Center, Shiraz, P-x; p 131.

- 1390 (2011)**, *In vivo* immunoparasitological effects of different types of L-arginine as nitric oxide precursor on cutaneous leishmaniasis caused by *Leishmania major*. *The 5th Iranian Congress of Clinical Microbiology*, 17-19 Aban (8-10 Nov.), Alborzi Microbiology Research Center, Shiraz, P-x; p 133.
- 1390 (2011)**, Study on antimalarial effects of *Artemisia oliveriana* as an Iranian flora on *Plasmodium berghei* in vivo. *The 7th National Biotechnology Congress of I.R. Iran*. 21-23 Shahrivar (12-14 Sept.) Energy Research Center, Tehran, Iran, P 940; pp.....
- 1390 (2011)**, Investigation on anti-leishmanial effects of artemisinin in comparison with glucantim on *Leishmania major* in vitro. *The 7th National Congress of Zoonotic Diseases*, 29-31 Ordibehesht (17-19 May), Lorestan University of Medical Sciences, Yasuj, Iran, P-X; p 91.
- 1389 (2010)**, Study on microsporidiosis in patients with gastroenteritis from referral laboratories of Gilan and Ghazvin provinces. *The 4th Congress of Clinical Microbiology in Iran*, 18-20 Aban (9-11 Nov.), Isfahan University of Medical Sciences, Isfahan, Iran, P-X; p 65.
- 1389 (2010)**, Current epidemiology of *Sporozoan* protozoa and frequency of other parasitic entropathogens among people with gastroenteritis in Iran. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 11.
- 1389 (2010)**, An investigation on *Cyclospora* infection isolated from gastroenteritic patients of Gilan and Ghazvin provinces in Iran. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 13.
- 1389 (2010)**, Comparison of the Th1 and Th2 responses of nonhealing & healing patients with cutaneous leishmaniasis in Mashhad during 2008. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 20.
- 1389 (2010)**, Detection of antibodies against *Toxoplasma gondii* in sub-urban cattle of Kerman using modified agglutination test (MAT). *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 149.
- 1389 (2010)**, The prevalence of Giardiasis among 6-12 years old pupils from primary schools of Bandar Imam Khomeini & determination of fero, zinc and copper during 2006-7. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 187.
- 1389 (2010)**, Immunobiochemical evaluation of killed leishmania vaccine (KLV) and BCG adjuvant in inhibition of visceralization of *Leishmania major* in Balb/c mice. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 223.
- 1389 (2010)**, *In vivo* investigation of Killed Leishmania Vaccine's (KLV) efficacy with Imiquimod (IMQ) as adjuvant in inhibition of visceralization of *L. major* in Balb/c model. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 245.
- 1389 (2010)**, Pharmacological and biochemical evaluation on antimalarial effects of *Artemisia turanica* on *Plasmodium berghei* in vivo. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 277.
- 1389 (2010)**, Pharmacochemistry on natural components of Iranian flora *Artemisia sieberi* and its antimalarial effects on *Plasmodium berghei* in. *The 7th National & 2nd Regional Congress of Parasitology in Iran (NICOPA 7)*, 27-29 Mehr (19-21 Oct.), TUMS, Tehran, Iran, P-X; p 287.
- 1388 (2010)**, The non-polar components of herbal extract *Artemisia khorassanica*. *The National Phytochemistry Conference*. 14-15 Esfand (5-6 Mar.) Qom, Iran, P X; pp.90.
- 1388 (2009)**, Antileishmanial effects of ASA in Susceptible Balb/c Mice Infected with *L. major* via Nitric Oxide (NO) and C-Reactive Protein (CRP) pathways. *The 18th Iranian Congress on Infectious Diseases and Tropical Medicine*. 21-25 Azar (12-16 Dec.) Tehran, Iran, O 11; pp.11.

- 1388 (2009)**, Current situation of *Cryptosporidium* and opportunistic parasites among gastroenteritic individuals in Mazandaran Province, Iran; an alarm for immunocompromised patients. *The 18th Iranian Congress on Infectious Diseases and Tropical Medicine*. 21-25 Azar (12-16 Dec.) Tehran, Iran, O 29; pp.29.
- 1388 (2009)**, Enteropathogenic parasites and related factors in gastroenteritic patients from Gilan and Ghazvin provinces of Iran. *The 18th Iranian Congress on Infectious Diseases and Tropical Medicine*. 21-25 Azar (12-16 Dec.) Tehran, Iran, P 75; pp.118.
- 1388 (2009)**, Sporozoan protozoa and related risk factors in hospitalized gastroenteritic children under 15 from Gilan province, Iran. *The 18th Iranian Congress on Infectious Diseases and Tropical Medicine*. 21-25 Azar (12-16 Dec.) Tehran, Iran, P 76; pp.119.
- 1388 (2009)**, Population-based laboratory surveillance for *Giardia* sp. and *Cryptosporidium* sp. isolated from gastroenteritic patients of Gilan and Ghazvin provinces of Iran. *The 18th Iranian Congress on Infectious Diseases and Tropical Medicine*. 21-25 Azar (12-16 Dec.) Tehran, Iran, P 77; pp.120.
- 1388 (2009)**, Frequency of sporozoan protozoa and other enteropathogenic parasites in gastroenteritic patients from Gilan and Ghazvin provinces. *The 3rd Iranian Congress of Clinical Microbiology*, 14-16 Mehr (6-8 Oct.), Alborzi Microbiology Research Center, Shiraz, P-x; p 224-5.
- 1388 (2009)**, Anti-leishmanial evaluation of Acetyl Salicylic Acid (ASA) in susceptible Balb/c mice infected with *L. major* via Nitric Oxide (NO) and C-Reactive Protein (CRP) mechanisms. *The 3rd Iranian Congress of Clinical Microbiology*, 14-16 Mehr (6-8 Oct.), Alborzi Microbiology Research Center, Shiraz, P-x; p 226.
- 1388 (2009)**, Study on immunoparasitological effects of anti-inflammatory acetyl salicylic acid (ASA) on susceptible Balb/c infected with *Leishmania major* via nitric oxide and C-reactive protein pathways. *The 6th National Biotechnology Congress of I.R. Iran*. 22- 24 Mordad (13-15 Aug.) Milad Conference Hall, Tehran, Iran, P M43; pp.....
- 1387 (2009)**, *The First Congress on Statistics and Information Technology*. 16 Bahman (4 Feb.) IT MOHME, Tehran, Iran.
- 1387 (2008)**, Frequency of Sporozoan protozoa and other Enteropathogenic parasites in gastroenteritic patients from Gilan and Ghazvin Provinces. *The 17th Iranian Congress on Infectious Diseases and Tropical Medicine*. 30 Azar- 4 Dey (20-24 Dec.) Tehran, Iran, P150; pp.192.
- 1387 (2008)**, Evaluation of anti-leishmanial effects and inhibition of visceralization of *Leishmania major* in infected Balb/c mice under treatment with Paromomycin. *The 2nd Iranian Congress of Clinical Microbiology*, 16-18 Mehr (8-10 Oct.), Alborzi Microbiology Research Center, Shiraz, P-xx; p 76.
- 1387 (2008)**, Inoculation of *Cryptosporidium* in Balb/c and C57BL/6 mice after immunosuppressive therapy as modeling Cryptosporidiosis in experimental animals. *The 2nd Iranian Congress of Clinical Microbiology*, 16-18 Mehr (8-10 Oct.), Alborzi Microbiology Research Center, Shiraz, P-xx; p 14.
- 1387 (2008)**, Epidemiological study on the prevalence rate of Cryptosporidiosis and other parasitic enteropathogens in patients with gastroenteritis in Western cities of Mazandaran province. *The 5nd National & 3rd International Congress of Biology*, 29-31 Mordad (19-21 Aug), University of Tehran, Iran, P-278; p 851.
- 1387 (2008)**, Study on the prevalence rate of parasitic enteropathogens in HIV positive cases and AIDS patients of Khorram Abad city in 2007. *The 6nd National Iranian Congress of Parasitology (NICOPA 6)*, 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, P-303; p 326.
- 1387 (2008)**, Identification of A₂ proteins in Iranian strains of *Leishmania infantum*. *The 6nd National Iranian Congress of Parasitology (NICOPA 6)*, 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, P-227; p 248.
- 1387 (2008)**, Investigation on IL-18 and IL-12 in patients with healing and non-healing forms of cutaneous leishmaniasis in Mash had city in 2007. *The 6nd National Iranian Congress of*

Parasitology (NICOPA 6), 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, P-197; p 214.

- 1387 (2008)**, Evaluation of immunobiochemical responses of sensitive Balb/c and resistant C57bl/6 mice infected with *Leishmania major* MRHO/IR/78/ER. *The 6nd National Iranian Congress of Parasitology (NICOPA 6)*, 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, P-196; p 213.
- 1387 (2008)**, Immunobiochemical evaluation of prostaglandin and nitric oxide in the physiopathology of Balb/c mice infected with *Leishmania major*. *The 6nd National Iranian Congress of Parasitology (NICOPA 6)*, 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, P-195; p 212.
- 1387 (2008)**, The role of IL-10 and IFN- γ in resistance and sensitive patients under treatment with Glucantime in Mash had. *The 6nd National Iranian Congress of Parasitology (NICOPA 6)*, 7-9 Khordad (27-29 May), Razi Institute, Hesarak, Karaj, Iran, O-47; p 50.
- 1386 (2007)**, Immunotherapy of cutaneous leishmaniasis by application of inducers and inhibitors of immune response parameters. *The 1th Regional Congress on Updates in Microbiology*, 28-29 Azar (19-20 Dec.) Lahijan, Iran, O; p. 3-4.
- 1386 (2007)**, A2 proteins in amastigote forms of *Leishmania infantum* from canine isolates of Meshkinshahr, North western Iran and *Leishmania donovani* (DD8). *The 1th Regional Congress on Updates in Microbiology*, 28-29 Azar (19-20 Dec.) Lahijan, Iran, O; p. 10-11.
- 1386 (2007)**, Immunobiochemical evaluation of prostaglandin (PG) and nitric oxide (NO) modulation in physiopathology of susceptible Balb/c mice infected with *Leishmania major*. *The 16th Iranian Congress on Infectious Diseases and Tropical Medicine*. 24-28 Azar (15-19 Dec.) Tehran, Iran, P57; pp.94.
- 1386 (2007)**, Evaluation of trinitroglycerin therapy on *Leishmania major* MRHO/IR/75/ER in *in vivo* and *in vitro* conditions. *The 3rd National Congress of Updates in Dermatology Diseases & Leishmaniasis*, 23-25 Aban (14-16 Nov.) Isfahan-Iran, p.101.
- 1386 (2007)**, Effects of trinitroglycerin therapy on serum zinc and copper, and liver enzymes in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER. *The 9th Iranian Congress of Biochemistry & the 2nd International Congress of Biochemistry and Molecular Biology*, 7-10 Aban (Oct.29-Nov,1) Shiraz-Iran, P24, p.S18.
- 1386 (2007)**, Biochemical evaluation of trace elements and liver enzymes during *Leishmania major* infection in susceptible Balb/c and resistant C57bl/6 mice. *The 9th Iranian Congress of Biochemistry & the 2nd International Congress of Biochemistry and Molecular Biology*, 7-10 Aban (Oct.29-Nov,1) Shiraz-Iran, P154, p.S60.
- 1386 (2007)**, Intrahippocampal infusion of lipopolysaccharide inhibits amygdale-kindled seizures in rats by elevation of nitric oxide level. *18th Iranian Congress of Physiology & Pharmacology*. 4-8 Shahrivar (26-30 Aug) Mashhad, Iran, O-13, p.3.
- 1386 (2007)**, Immuno-biochemical evaluation of efficacy by nitric oxide synthetic metabolite (S-Nitrate) on murine malaria caused by *Plasmodium berghei*. *18th Iranian Congress of Physiology & Pharmacology*. 4-8 Shahrivar (26-30 Aug) Mashhad, Iran, P-660, p.166.
- 1386 (2007)**, Pharmacological evaluation of Trinitroglycerin (TNG) as Nitric Oxide (NO) releasing agent and production of reactive nitrogen intermediates (RNI) in BALB/c mice infected with *Leishmania major*. *18th Iranian Congress of Physiology & Pharmacology*. 4-8 Shahrivar (26-30 Aug.) Mashhad, Iran, P-679, p.171.
- 1386 (2007)**, Immuno-biochemical comparison of nitric oxide and reactive nitrogen intermediates (RNI) production in susceptible BALB/c and resistant C57BL mice infected with *Leishmania major*. *18th Iranian Congress of Physiology & Pharmacology*. 4-8 Shahrivar (26-30 Aug) Mashhad, Iran, P-663, p.167.
- 1385 (2007)**, Induction of A₂ proteins as key marker in Iranian species of visceral Leishmaniasis. *The 1st Iranian Proteomics Congress*. 2 Esfand (21 Feb.) Tehran, Iran, p.17 & 19.
- 1385 (2006)**, The importance of Cryptosporidial gastroenteritis in acquired immunodeficiency patients in Iran. *The 1st Lab Med Congress*. 21-24 Dey (11-14 Jan.) Tehran, Iran, Sec. 2; pp.60.

- 1385 (2006)**, Investigation on prevalence rates of Cryptosporidiosis, Isosporiasis and pathogenic parasites among Gastroenteric patients in Babol and Babolsar cities. *The 15th Iranian Congress on Infectious Diseases and Tropical Medicine*. 25-29 Azar (16-20 Dec.) Tehran, Iran, P8; pp.47.
- 1385 (2006)**, Investigation on prevalence rates of enteropathogenic parasites among Gastroenteric patients in eastern part of Mazandaran province in year 1384-85. *The 15th Iranian Congress on Infectious Diseases and Tropical Medicine*. 25-29 Azar (16-20 Dec.) Tehran, Iran, P25; pp.64.
- 1385 (2006)**, In vivo evaluation of antileishmanial activity of *Artemisia auckery* on *Leishmania major*. *The 15th Iranian Congress on Infectious Diseases and Tropical Medicine*. 25-29 Azar (16-20 Dec.) Tehran, Iran, P26; pp.65.
- 1385 (2006)**, A study on prevalence rate of *Blastocystis hominis* among Gastroenteric patients in Sari city in year 1385. *The 15th Iranian Congress on Infectious Diseases and Tropical Medicine*. 25-29 Azar (16-20 Dec.) Tehran, Iran, P27; pp.66.
- 1384 (2005)**, Comparable association between nitric oxide and *Plasmodia* species using direct and Nested-PCR assay for malaria detection in endemic areas of Iran. *The 14th Iranian Congress on Infectious Diseases and Tropical Medicine*. 26-30 Azar (17-21 Dec.) Tehran, Iran, P176; pp.214.
- 1384 (2005)**, Immunoepidemiological study on reactive nitrogen intermediates as stable metabolites of nitric oxide induction in malaria infected patients from endemic areas of Iran. *The 5nd National Iranian Congress of Parasitology (NICOPA 5)*, 24-26 Aban (15-17 Nov.), Shahid Beheshti University of Medical Sciences, Tehran, Iran, O-45; p 73-74.
- 1384 (2005)**, The evaluation of anti-leishmanial activity of *in vivo* administration of selective nitric oxide inducer on *Leishmania major* in Balb/c mice. *The 2nd National Congress of Updates in Dermatology Diseases & Leishmaniasis*, 7-8 Mehr (29-30 Sept.), Isfahan, Iran, p. 202-203.
- 1384 (2005)**, Co- induction of CRP and NO in malaria patients from endemic provinces of Iran. *The 4th National Congress of Biotechnology*, 24-26 Mordad (15-17 Aug.), Kerman, Iran, p190.
- 1383 (2005)**, Simultaneous increases in macrophage proliferation and nitric oxide production in the spleen during murine malaria (*Plasmodium berghei*) infection. *The 1th Iranian Seminar on Immunity and Infections*. 18-19 Esfand (9-10 March), Sari, Iran, O4-1; pp.22.
- 1383 (2005)**, Time courses of reactive nitrogen intermediate (RNI) production as nitric oxide (NO) response after *in vivo* treatment with lipopolysaccharide (LPS) from *Salmonella abortus equi*. *The 1th Iranian Seminar on Immunity and Infections*. 18-19 Esfand (9-10 March), Sari, Iran, O6-1; pp.36.
- 1383 (2004)**, The epidemiology of urban malaria in Parsabad-e-Moghan. *The 13th Iranian Congress on Infectious Diseases and Tropical Medicine*. 20-24 Azar (11-15 Dec.), Tehran, Iran, P3; pp.55.
- 1383 (2004)**, Nitric oxide induction as a novel immunological target in patients of malaria endemic areas of Iran. *The 13th Iranian Congress on Infectious Diseases and Tropical Medicine*. 20-24 Azar (11-15 Dec.), Tehran, Iran, P16; pp.68.
- 1383 (2004)**, The key role for nitric oxide (NO) as a free radical in cerebral malaria, *The 7th Iranian Congress of Immunology and Allergy*, 14-17 Ordibehesht (4-7 May), Mashad University of Medical Sciences, Mashad, Iran, p. 118.
- 1383 (2004)**, The penetration of *Plasmodium* into red blood cell is a protective mechanism of malaria parasite against high level of nitric oxide in blood circulation, *The 12th Iranian Congress of Infectious Diseases and Tropical Medicine*. 27-30 Dey (17-21 Jan.) Tehran, Iran, p19.
- 1382 (2003)**, Induction of nitric oxide synthase 2 (NOS2) mRNA in target organs of host during malaria, *The 4th National Iranian Congress of Parasitology & Parasitic Diseases*, 21-24 Mehr, (13-16 Oct.), Mashad, Iran, p.87 & 400.
- 1381 (2002)**, Nitric oxide in malaria, *Workshop on Malaria Updates*, 25-26 Khordad (15-16 June), Pasteur Institute of Iran, Tehran.
- 1379 (2000)**, Spleen, Nitric Oxide and Malaria, *The 5th Iranian Congress of Immunology and Allergy*, 27-29 Ordibehesht (17-19 May), Tarbiat Modarres University, Tehran, Iran.

- 1375 (1996)**, Malaria vaccines an overview, *The 2nd Congress of Blood and Related Diseases* 1-2 Dey (21-23 Dec.), Tehran, Iran.
- 1375 (1996)**, Application of Auramin Phenol Fluorescence (APF) in the diagnosis of malaria. *The 5th Iranian Congress of Infectious Diseases and Tropical Medicine*. 11-12 Azar (2-3 Dec.), Tehran, Iran.
- 1375 (1996)**, Cryptosporidiosis, one of the most important parasitic zoonosis among the AIDS patients. *The 3rd National Congress of Zoonoses in Iran*. 1-4 Khordad (23-25 April), Mash-had, Iran.
- 1374 (1995)**, Immunoparasitology of Cryptosporidiosis in AIDS. *The 8th International Congress of Geographic Medicine & 3rd Iranian Congress of Immunology and Allergy*, Shiraz, Iran.
- 1372 (1993)**, The first cases of Cryptosporidiosis among AIDS patients in Iran, *The 4th Iranian Congress of Infectious & Tropical Diseases*, Tehran, Iran.
- 1370 (1991)**, The relationship between the number of parasites in house wastewater & parasitic diseases, *The National Conference of Cities and Water Problem*, Shiraz, Iran.
- 1369 (1990)**, A comparison of parasitic fauna in house wastewater of three regions in Tehran, *The Water and Wastewater Hygiene Seminar*, Ahwaz, Iran.
- 1369 (1990)**, Prevalence of intestinal parasites in people of Bandar Anzali in the North of Iran, *The 1st National Iranian Congress of Parasitology & Parasitic Diseases*, Rasht, Iran.
- 1369 (1990)**, Sero-epidemiology of fascioliasis in province of Gilan. *The 1st National Iranian Congress of Parasitology & Parasitic Diseases*, Rasht, Iran.

INTERNATIONAL CONGRESS

- 2015**, Application of recombinant A2-ELISA and its comparison with rKE16 dipstick and direct agglutination tests for diagnosis of visceral leishmaniasis in Meshkinshahr, north-western Iran. The 25th ECCMID, April 25–28, Copenhagen, Denmark; Poster No: EV0564.
- 2014**, Prevalence of sporozoan protozoa and enteroparasites in the gastroenteritic patients referring to the health centers of seven provinces of Iran. The 6th EuroAsian Congress on Infectious Diseases, September 24–27, Belgrad, Serbia; P-410, p 621.
- 2012**, Genetic characteristics of *Plasmodium vivax* apical membrane antigen-1 gene in isolates from Iran. 11th European Multicolloquium Congress on Parasitology (EMOP XI), July 25–29, Cluj-Napoca, Romania, 2012; P-418.
- 2012**, Coparison of animals and human sera in the accessory factor in the Sabin-Feldman Dye Test for detection of toxoplasmosis. 11th International Congress of Immunology & Allergy (ICIA 11), 7-10 Ordibehesht (26-29 April), Milad Int. Conf. Hall, Tehran, Iran, P-640; p 157.
- 2012**, Pharmacochemistry of Iranian flora *Artemisia oliveriana* and its antimalarial effects on *Plasmodium berghei* in vivo. International Congress on Malaria Elimination (ICMA), Jan 25–27, Kish, Hormozgan, Iran, 2012; P-13.
- 2012**, Variation in AMA-1 gene in *Plasmodium vivax* isolates from Iran. International Congress on Malaria Elimination (ICMA), Jan 25–27, Kish, Hormozgan, Iran, 2012; P-59.
- 2010**, A2 gene among isolates from Iranian cutaneous leishmania species. The XIIth International Congress of Parasitology (ICOPA 7), Aug 15–20, Melbourne, Australia, 2010; P-1116.
- 2010**, Protein variations of Iranian strains of *Cyptosporidium* spp. After isolation in experimentally immunosuppressed balb/c and C57bl/6 mice. The XIIth International Congress of Parasitology (ICOPA 7), Aug 15–20, Melbourne, Australia, 2010; P-1469.
- 2010**, Evaluation of anti-leishmanial efficacy by *in vivo* administration of *Artemisia auchery* herbal extract on *Leishmania major* in balb/c mice. The XIIth International Congress of Parasitology (ICOPA 7), Aug 15–20, Melbourne, Australia, 2010; P-1828.
- 2010**, A study on the prevalence rate of *Blastocystis* spp. in patients with gastroentritis in eastern part of Mazandaran province in year 2005. The XIIth International Congress of Parasitology (ICOPA 7), Aug 15–20, Melbourne, Australia, 2010; P-1829.

- 2010**, Antimalarial drug resistance and combination therapies; Problems and solutions. (4th DICID), Jul 15–18, *Beijing International Convention Center, Beijing, China, (Invited speaker)* 2010; p42.
- 2010**, A2 gene among isolates from Iranian cutaneous leishmania species is highly conserved gene. (4th DICID), Jul 15–18, *Beijing International Convention Center, Beijing, China, 2010*; 14(S2): PP-201, S86.
- 2010**, Systemic leishmaniasis are inhibited by acetylsalicylic acid via nitric oxide pathway in *Leishmania major* infected susceptible Balb/c mice. The 3rd Ditan International Conference on Infectious Diseases (4th DICID), Jul 15–18, *Beijing International Convention Center, Beijing, China, 2010*; 14(S2): PL-008, S16.
- 2010**, Acetyl salicylic acid inhibits systemic leishmaniasis via nitric oxide pathway in susceptible Balb/c model infected with *Leishmania major*. *The 6th International Conference Biology, Chemistry, and Therapeutic Applications of Nitric Oxide*, 14-18 June, Kyoto, Japan P150, p.92.
- 2009**, Population-based laboratory surveillance for *Giardia spp.* And *Cryptosporidium spp.* Isolated from gastroenteritic patients of Gilan and Ghazvin provinces from Iran. *The 6th Congress Microbiologia Balkanica and 4th Congress of Macedonian Microbiologists*, 28-31 Oct, Ohrid, Macedonia. P 3.8; pp.xx.
- 2009**, Comparison of animal rabies from northern provinces of Iran referred to the Amol Research Center (ARC) during 2007-2008. *The 3rd EurAsia Congress of Infectious Diseases*. 1-4 Oct, Baku, Azerbaijan. P 212; pp.222.
- 2009**, Phisyopathobiology of cryptosporidiosis in immunosuppressed animal models. *The 3rd International Congress of Giardia and Cryptosporidium Conference*. 11 -15 Oct, Orvieto, Italy. P 104; pp.110.
- 2009**, Co-infection of *Blastocystis hominis* and *Giardia lamblia* in patients of Tonekabon city from Mazandaran Province, Northern Iran. *The 3rd International Congress of Giardia and Cryptosporidium Conference*. 11 -15 Oct, Orvieto, Italy. P 107; pp.111.
- 2009**, Phisyopathobiology Prevalence rate of cryptosporidiosis and other enteropathogenic parasites in gastroenteritic patients from western cities of Mazandaran Province, Northern Iran. *The 3rd International Congress of Giardia and Cryptosporidium Conference*. 11 -15 Oct, Orvieto, Italy. P 108; pp.111.
- 2009**, Molecular survey of A2 proteins in leishmania species from endemic areas in Iran, *The 6th European Congress on Tropical Medicine and International Health*. 6-10 Sept., Verona, Italy. P. 4.11-067;pp.XX.
- 2009**, Leishmaniasis as a neglected tropical disease in the world, Eastern Mediterranean Region and Iran. The 3rd Ditan International Conference on Infectious Diseases (3rd DICID), Jul 30 – Aug 2, *Beijing International Convention Center, Beijing, China, CS6-01*, S9.
- 2009**, Anti-leishmanial effects of paromomycin in both cutaneous and visceral forms of *Leishmania major* infection in Balb/c mice. The 3rd Ditan International Conference on Infectious Diseases (3rd DICID), Jul 30 –Aug 2, *Beijing International Convention Center, Beijing, China, PP-167*, S94.
- 2009**, Immunotherapy of cutaneous leishmaniasis by inhibition of prostaglandin and induction of nitric oxide in susceptible Balb/c infected with *Leishmania major*. The 3rd Ditan International Conference on Infectious Diseases (3rd DICID), Jul 30 –Aug 2, *Beijing International Convention Center, Beijing, China, PP-168*, S94.
- 2009**, Anti-malarial effects of Iranian flora *Artemisia khorassanica* on experimental *Plasmodium berghei* infection and analysis of its pharmacochemistry. The 3rd Ditan International Conference on Infectious Diseases (3rd DICID), Jul 30 –Aug 2, *Beijing International Convention Center, Beijing, China, PP-169*, S94.
- 2009**, Frequency of sporozoan protozoa and other enteropathogenic parasites in patients with gastroenteritis isolated from Guilan and Ghazvin provinces in Iran. The 3rd Congress of European Microbiologists (FEMS), 28 June –2 July, Guthenburg, Sweden.
- 2009**, Evaluation of anti-leishmanial efficacy by *in vivo* administration of herbal extract *Artemisia auchery* on *Leishmania major* in Balb/c mice. 26th International Congress of Chemotherapy and

Infection (26th ICC) "The Changing Climate of Infectious Diseases", 18–21 June, Toronto, Canada, P233.

- 2009**, Biochemical evaluation of anti-malarial effects of *Artemisia khorassanica* extracts *in vivo* in murine malaria. 10th Iranian Congress of Biochemistry and the 3rd International Congress of Biochemistry and Molecular Biology, Jul 11 –14, TUMS, Tehran, Iran, P-10-151-1.
- 2009**, Study of glutathione-s-transferase enzyme activity in rodent and human malaria (*Plasmodium berghei* & *Plasmodium falciparum*). 10th Iranian Congress of Biochemistry and the 3rd International Congress of Biochemistry and Molecular Biology, Jul 11 –14, TUMS, Tehran, Iran, P-10-172-1.
- 2009**, Immunobiochemistry of nitric oxide, microelements and liver enzymes and inhibitory evaluation of visceralization in *Leishmania major* infected Balb/c mice under treatment with Paromomycin. 10th Iranian Congress of Biochemistry and the 3rd International Congress of Biochemistry and Molecular Biology, Jul 11 –14, TUMS, Tehran, Iran, P-10-177-1.
- 2009**, Anti-leishmanial effects of L-arginine as nitric oxide inducer and Indomethacin as prostaglandin inhibitor in Balb/c mice infected with *Leishmania major* MRHO/IR/75/ER. 10th Iranian Congress of Biochemistry and the 3rd International Congress of Biochemistry and Molecular Biology, Jul 11 –14, TUMS, Tehran, Iran, P-10-201-1.
- 2009**, Molecular genetic of A2 proteins analysis from Iranian *Leishmania* species. 10th Iranian Congress of Biochemistry and the 3rd International Congress of Biochemistry and Molecular Biology, Jul 11 –14, TUMS, Tehran, Iran, P-10-586-1.
- 2008**, In vivo investigation on anti-leishmanial activity of Paromomycin by inhibition of *Leishmania major*. 2nd International Students Conference of Biotechnology, Nov 15 –17, TUMS, Tehran, Iran, P602.
- 2008**, An study on components of Iranian flora *Artemisia Khorassanica* and its antimalarial effects. 2nd International Students Conference of Biotechnology, Nov 15 –17, TUMS, Tehran, Iran, P134.
- 2008**, Study of Eosin-B as a new drug against *Plasmodium berghei* and its effects on GST. 2nd International Students Conference of Biotechnology, Nov 15 –17, TUMS, Tehran, Iran, P119.
- 2008**, Immunobiochemical and pharmacological effects of trinitroglycerin as nitric oxide donor in BALB/c mice infected with *Leishmania major* MRHO/IR/75/ER. 17th International Congress for Tropical Medicine & Malaria (ICTM 17) Sept 29 – Oct. 3, Jeju, Korea, P078, p.254.
- 2008**, Antimalarial effects of nitric oxide synthetic metabolite (S-Nitrate) as a novel therapy for in vivo treatment of *Plasmodium berghei* NY. 17th International Congress for Tropical Medicine & Malaria (ICTM 17) Sept 29 – Oct. 3, Jeju, Korea, P095, p.262.
- 2008**, Antimalarial effects of nitric oxide synthetic metabolite (S-nitrate) as a novel therapy for in vivo treatment of *Plasmodium berghei* in mice. 13th International Congress on Infectious Diseases (13th ICID) June 19 – 22, Kuala Lumpur, Malaysia, ISE.467, p.110.
- 2008**, Immunopharmacological and pathophysiological investigation on antileishmanial effects of Trinitroglycerin as nitric oxide releasing agent in Balb/C mice infected with *Leishmania major*. The International Online Medical Conference (IOMC), May 10-11, Online, p.35-48.
- 2008**, Immuno-biochemical comparison of susceptible BALB/c and resistant C57BL/6 mice responses to *Leishmania major* infection. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 19 – 22, P 1925, p.x.
- 2007**, Study on rabies from animal and human cases in Iran, The 11th National Conference Current Topics of Virology, Sep. 28, Ulaambaatar, Mongolia, P x, p.101.
- 2007**, A new antimalarial agent; effects of extracts of *Artemisia diffusa* against *Plasmodium berghei*, 55th International Congress and Annual Meeting of the Society for Medicinal Plant Research, Sept. 2–6, Graz, Austria, P219, p.892.
- 2007**, Lipopolysaccharide inhibits amygdala-kindled seizures in rats, The 11th Congress of the European Federation of Neurological Sciences. 25-28 Aug., Brussels, Belgium. P1194, p.81.

- 2007**, Effect of Extracts of *Artemisia diffusa* against *Plasmodium berghei*, as a New Antimalarial Agent, *BIY's 5th Anniversary, The Conference & Expo of International Drug Discovery Science and Technology*, May 28- June 5, Shanghai, China, pp.XX.
- 2007**, Identification of A2 proteinsin *Leishmania infantum* from canine isolates of Meshkinshahr, northwestern Iran, *The 5th European Congress on Tropical Medicine and International Health*. 24-28 May, Amsterdam, Netherlands. PB 161:pp.255.
- 2007**, *Cryptosporidium* and other enteropathogenic parasites in gastroenteritic patients from Mazandaran province, Iran. *II International Congress of Giardia and Cryptosporidium Conference*. 13 -18 May, Centro Cultural Universitario, Universidad Michoacana de San Nicolás de Hidalgo, Morelia-Michoacán, México. P 46; pp.31.
- 2006**, Investigation on anti-Leishmanial activity of drugs modulating nitric oxide *in vivo* in Balb/c mice infected with *Leishmania major*. *11th International Congress of Parasitology (ICOPA XI)*. 6 -11 August, Glasgow, UK. P A5.45; pp.115.
- 2006**, An investigation on A2 proteins from cultured amastigotes and promastigotes of *Leishmania infantum* from IR Iran. *11th International Congress of Parasitology (ICOPA XI)*. 6 -11 August, Glasgow, UK. P A4.38; pp105.
- 2005**, Co-association of C-reactive protein and nitric oxide induction in malaria patients from endemic provincial areas of Iran. *The 12th International Congress of Protozoology (ICOP XII)*, July 10-15, Guangzhou, China, pp. 152.
- 2004**, The epidemiology of urban malaria in Parsabad-e-Moghan, Iran. *The 6th European Congress of Chemotherapy and Infection (ECC & RICAI)*, Paris, France, 1-3 Dec., 509/88p.S175.
- 2004**, Investigation on nitric oxide induction as a novel immunological target in malaria infected patients from endemic areas of Iran. *The 6th European Congress of Chemotherapy and Infection (ECC & RICAI)*, 1-3 Dec., Paris, France, 512/88p.S176.
- 2004**, The proliferation of macrophages in spleen as a target organ is associated with high level of nitric oxide production during murine malaria infection. *The 9th European Multicollloquium of Parasitology (EMOP IX)*, 18-23 July. Valencia, Spain, 32(O), P.100.
- 2003**, Application of nitric oxide modulation as a pharmacological approach in the treatment of malaria, *The 5th European Congress of Chemotherapy and Infection (ECC5)*, 17-20 Oct., Rhodes, Greece, p.72.
- 2002**, The role of nitric oxide and its up/downstream molecules in malaria: cytotoxic or preventive? *The Joint International Tropical Medicine Meeting (JITMM)*, 20-22 Nov., Bangkok, Thailand, p.58.
- 2002**, Molecular epidemiology of malaria disease in endemic areas of Iran, *The Joint International Tropical Medicine Meeting (JITMM)*, 20-22 Nov., Bangkok, Thailand, p.193.
- 2002**, Detection of congenital toxoplasmosis by Nested-PCR in Iran, *The 3rd European Congress on Tropical Medicine and International Health*, 8-11 Sept., Lisbon - Portugal, S1, P079.
- 2001**, Pharmacological assessment of the role of nitric oxide in mouse models of malaria *in vitro*, International Thermal Physiology Symposium, *Australian Physiological Society*, 1-2 Aug., Vogoung, Australia, 32(S 2), 20p.
- 2001**, Nitric oxide and its up/downstream molecules in malaria: pathogenic or protective? *British Society for Parasitology, 12th Malaria meeting*, 10-12 Sep. Leeds University, Leeds, UK.
- 2001**, Nitric oxide and its up/downstream targets for novel treatment of drug-sensitive and drug-resistant malaria, *The 8th Iranian students seminar in Europe*, 5-7 May, UMIST, Manchester, UK, Proceedings of Microbiology & Immunology Group, pp. 8-9.
- 2000**, Induction of nitric oxide synthase 2 (iNOS) mRNA in target organs of murine malaria, *The 18th International Congress of Biochemistry and Molecular Biology, Satellite meeting; Gene Action and Cellular Function in Parasitic Protozoa*, 13-15 July, Manchester, UK, 2041, p. 470.
- 2000**, Induction of inducible nitric oxide synthase (iNOS) mRNA in target organs of murine malaria, *The 7th Iranian students seminar in Europe*, 20-21 May, UMIST, Manchester, UK, Proceedings of Microbiology & Immunology Group, p.9.

- 1999**, Direct detection of nitric oxide and measurement of stable nitrogen metabolites in murine malaria, *British Society for Parasitology (BSP)*, 11th Malaria meeting, Imperial College of Science, Technology & Medicine, 20-22 Sep., London, UK, p. 81.
- 1999**, The involvement of nitric oxide in cerebral malaria, *The 5th Iranian students seminar in Europe*, 8 May, UMIST, Manchester, UK, Medical Sciences group, Proceedings of Microbiology & Immunology Group, p. 43.
- 1998**, The molecular biology of possible involvement and role of a novel target in malaria, *The 4th Iranian students seminar in Europe*, 5 July, London, UK, Proceedings of Microbiology & Immunology Group, Abstract 16.
- 1996**, The first cases of Isosporiasis & Cryptosporidiosis among the AIDS patients in Iran. *The 7th European Multicolloquium of Parasitology (EMOP VII)*, 2-6 Sept. *Parassitologia*;38(1,2):E10/16, P. 418, Parma, Italy.
- 1994**, Cryptosporidiosis in patients with acquired immunodeficiency, *The 8th International Congress of Parasitology (ICOPA VIII)*, Po.23.08(2), Izmir, Turkey.
- 1994**, The immunogenicity of *Toxoplasma gondii* Penetration Enhancing Factor (PEF), *The 8th International Congress of Parasitology (ICOPA VIII)*, O72.4(49), Izmir, Turkey.

AS JOURNAL REFEREE

1. Lancet Infectious Diseases (**LID**)
2. Nitric Oxide Journal (**NOJ**)
3. Iranian Biomedical Journal (**IBJ**)
4. Iranian Journal of Public Health (**IJPH**)
5. Pakistani Journal of Biological Sciences (**PJBS**)
6. Journal of Medical Sciences (**JMS**)
7. Research Journal of Parasitology (**RJP**)
8. Asian Journal of Plant Sciences (**AJPS**)
9. Asian Journal of Animal and Veterinary Advances (**AJAVA**)
10. Iranian Journal of Parasitology (**IJP**)
11. Iranian Journal of Medical Hypotheses and Ideas (**IJMHI**)
12. African Journal of Biochemistry Research (**AJBR**)
13. Journal of Cell and Animal Biology (**JCAB**)
14. Journal of Shahre Kord University of Medical Sciences (**JSKUMS**)
15. African Health Sciences (**AHS**)
16. International Journal of Medicine and Medical Sciences (**IJMMS**)
17. Journal of Medicinal Plants Research (**JMPR**)
18. Korean Journal of Parasitology (**KJP**)
19. Open Parasitology Journal (**OPJ**)
20. Journal of Clinical Medicine and Research (**JCMR**)
21. Oman Medical Journal (**OMJ**)
22. Journal of Infectious Diseases and Immunity (**JIDI**)
23. Research and Reports in Tropical Medicine (**RRTM**)
24. International Journal of Enteric Pathogens (**IJEP**)

TEACHING COURSES

Parasitology, Protozoology, Systematic of parasites, Medical microbiology, Immunology of parasites, Malariology, Leishmaniology, Genetics of Parasites, Biology of Parasites, Information Technology in Biomedical Sciences,

MEMBERSHIP OF PROFESSIONAL SOCIETIES

Korean Society for Parasitology (**KSP**), Since 2009
Biosafety Society of Iran (**BSI**), Since 2007

Iranian Society for Immunology & Allergy (**ISIA**), Since 2004
Iranian Society for Biotechnology (**ISB**), Since 2002
British Society for Parasitology (**BSP**), Since 1998
Iranian Society for Parasitology (**ISP**), Since 1997

EDITORIAL BOARD OF NATIONAL & INTERNATIONAL JOURNALS

1. Journal of Epidemiology and Public Health Reviews, (**JEPHR**), Since 2017
2. Edorium Journal of Microbiology (**EJM**), Since 2014
3. Insight Parasitology (**IP**), Since 2014
4. Canadian Open Infectious Diseases and Immunity Journal (**COIDIJ**), Since 2014
5. Journal of Nusantara Bioscience (**JNC**), Since 2013
6. Journal of Acute Disease (**JAD**), Since 2011
7. Biotechnology Journal of Environmental Micro-organisms, Lahijan Islamic Azad University (**BJEM**), Since 2010
8. Journal of Basic and Clinical Pharmacy (**JBCP**), Since 2010
9. Current Research Journal of Biological Sciences, Maxwell Science (**CRJBS**), Since 2009
10. International Journal of Medicine and Medical Sciences (**IJMMS**), Since 2009
11. Journal of Biological Sciences of Rasht Islamic Azad University (**JBSRIAU**), Since 2008
12. Pakistan Journal of Biological Sciences (**PJBS**), Since 2006

OTHER RESPONSIBILITIES

2014-16, Member of Council for Academic Evaluation at Pasteur Institute of Iran (PII)
2013-15, Member of Research Council at Pasteur Institute of Iran (PII)
2013, Member of Committee for Annual Academic Evaluation at Pasteur Institute of Iran (PII)
2013-15, Manager of Parasitology, Mycology & Immunology Group at Pasteur Institute of Iran (PII)
2012-14, Member of Committee for Quality Assurance at Pasteur Institute of Iran (PII)
2012-14, Member of Council for Academic Evaluation at Pasteur Institute of Iran (PII)
2012, Member of Committee for Annual Academic Evaluation at Pasteur Institute of Iran (PII)
2011-13, Member of Publication Committee at Pasteur Institute of Iran (PII)
2011-Now, Member of Suggestions Committee at Pasteur Institute of Iran (PII)
2011-13, Member of Higher Education Council at Pasteur Institute of Iran (PII)
2009-11, Member of Leishmania Work Group (LWG) at Pasteur Institute of Iran (PII)
2009-11, Member of Higher Education Council at Pasteur Institute of Iran (PII)
2009-10, Member of Commission for Definition of Health Informatics, Electronic Health Record, Ministry of Health & Medical Education (MOHME)
2008-13, Member of IT Council at Ministry of Health & Medical Education (MOHME)
2008-13, Manager of IT Department at Pasteur Institute of Iran (PII)
2007-11, Member of Judgment and Supervision Council for Research Projects at PII
2007-09, Member of Research Council at Pasteur Institute of Iran (PII)
2007-11, Member of Publication Committee at Pasteur Institute of Iran (PII)
2007-08, Deputy of Medical Biotechnology Network of IR Iran
2007-08, Inspector of Pasteur Scientific Company (PasCo)
2006-07, Member of Evaluation Committee at Pasteur Institute of Iran (PII)
2006-07, Member of Publication Committee at Pasteur Institute of Iran (PII)
2004-07, Member of managing team of Pasteur Scientific Company (PasCo)
1994-Now, Chief of Parasitology Laboratory, Department of Parasitology, Pasteur Institute of Iran

LANGUAGES

English Courses

1997, Pre-session English course, English Language Teaching Unit (ELTU) of The University of Manchester, 22 Sep.-12 Dec. Manchester, UK.

1996, Full time course in English for academic purposes, English Language Unit, under secretary for student's affairs, Ministry of Health & Medical Education, Tehran, Iran.

English Tests

1997, IELTS by University of Manchester, Manchester, UK.

1996, MOHMET by Ministry of Health & Medical Education, Tehran, Iran.

Other languages

Persian: writing, reading & speaking; **Arabic**: writing & reading; **Turkish**: reading & speaking